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Abstract

Lethal factor (LF), a component of anthrax toxin, is the primary virulence factor
that allows Bacillus anthracis to evade the immune response by blocking the activation of
mitogen-activated protein kinase (MAPK) enzymes. This research modifies three
published MAPK models to reflect this signal inhibition and to estimate a first-order
reaction rate by fitting the models to published viability data for two macrophage cell
lines cultured with the LF-producing Bacillus anthracis-Vollum1B strain. One model
appears to be ill-suited for this purpose because not all relevant MAPK components could
be integrated into the inhibition equations. Despite different underlying parameters and
values, the remaining two models display consistent behavior, due to the highly
conserved signal pathway structure, and provide approximately equal rate constants and
measures of the relative sensitivity between cell lines. The results demonstrate model
robustness and an ability to guide experimental design toward quantifying the LF reaction
rate and estimating the sensitivity of human alveolar macrophages. The models serve as a
first step toward an inhalation dose-response model and, by providing a measure of
differential susceptibility, can lend increased confidence in extrapolation between cell
types in vitro or between species in vivo.
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THREE MODELS OF ANTHRAX TOXIN EFFECTS ON
THE MAP-KINASE PATHWAY AND MACROPHAGE SURVIVAL

I. Introduction

Motivation
Centuries before the role of pathogenic microorganisms was discovered, the
impact of disease on a community was well understood by those wishing to kill and
demoralize an enemy. In the mid-fourteenth century, forces surrounding the walls of
Caffa, a coastal city on the Crimean Sea, suddenly took heavy losses from plague and,
hoping “that the intolerable stench would kill everyone inside,” began catapulting the
“mountains” of victims into the city (Derbes, 1966:180; Wheelis, 2002:973). After
enduring three years of siege, the defenders were quickly overcome by pestilence and fled
by sea; their destination ports became the initial sites of the Black Death that killed over
one quarter of Europe in just six months (Derbes, 1966:181-182). Despite occurring 600
years ago, the Great Plague remains the public’s ideation of a pathogen’s potential for
devastation. The anthrax letters that infected 23 and killed 5 in late 2001 (USAMRIID,
2005:10) and continuous news reports about severe acute respiratory syndrome (SARS),
avian flu pandemic, and weapons of mass destruction (WMD) have heightened public
awareness of the threat posed by microorganisms. Motivated by this threat, this research
aims to advance knowledge of inhalational anthrax pathogenesis by developing a model
of a critical biomolecular reaction exerted by anthrax toxin on alveolar macrophages.
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Biological Weapons History and Increasing Threat.
The biological weapons threat is very real. Japan had an aggressive research
program during World War II that included disseminating plague infected fleas from
aircraft, causing epidemics in villages in China and Manchuria (USAMRIID, 2005:4).
According to a 1994 study by Meselson, as relayed by U.S. Army Medical Research
Institute for Infectious Diseases (USAMRIID), “an accidental aerosol release” of anthrax
spores from a Soviet military facility in 1979 caused “66 fatalities in the 77 patients
identified” in Sverdlovsk, the town downwind from the compound (USAMRIID, 2005:7).
Under United Nations scrutiny in 1991, Iraq confirmed running an extensive offensive
bio-weapons program; over 6,500 liters of anthrax and 11,500 liters of toxins had been
loaded into munitions and deployed throughout Iraq earlier that year (USAMRIID,
2005:8). Today “at least 17 nations are believed to have offensive biological weapons
programs” (Inglesby and others, 1999:1736), but the modern biological weapons threat
does not come only from nation states with established laboratories.
Examples of terrorists using or planning to use biological weapons are recorded
with increasing frequency over the last 25 years. In 1984 the Rajneeshee cult sprayed
salmonella on food in Oregon restaurants in an attempt to influence local elections (Shea,
2004:CRS-2). Aum Shinrikyo gained notoriety by attacking Tokyo subways with sarin
nerve agent, killing 12 and injuring over 6,000 (Cronin, 2003:CRS-1). Investigation also
revealed at least eight unsuccessful anthrax and botulism aerosol attacks in the streets of
Tokyo from 1993 to 1995 (Inglesby and others, 1999:1736; USAMRIID, 2005:10). The
anthrax mail attacks in the U.S. brought the threat into sharp focus and resulted in
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increased biodefense efforts by law enforcement and public health agencies across the
United States and perhaps the world. Subsequently, authorities thwarted a terrorist cell’s
plan to put cyanide in the water supply to the U.S. Embassy in Rome in 2002 (Cronin,
2003:CRS-4). Between January 2003 and February 2004, “terrorist plots to use ricin
were uncovered in England,” and “ricin was found in a South Carolina postal
facility…and in the Dirksen Senate Office building in Washington, D.C.” (USAMRIID,
2005:11). These examples are only a few of the bio-terror incidents in recent years.
Reasons for this increased usage are addressed in Terrorist Motivations for
Chemical and Biological Weapons Use: Placing the Threat in Context, a March 2003
Congressional Research Service (CRS) Report For Congress by Audrey Kurth Cronin, a
terrorism expert for the CRS. The terrorist chemical and biological weapons (CBW)
threat has increased because the “internationalization of terrorism” has all but erased the
moral and political boundaries observed by traditional terrorists like the Irish Republican
Army (IRA) and the Basque National Party in Spain (Cronin, 2003:CRS-3). Religious
militants are willing to kill large numbers of “heretics or infidels” and sacrifice their own
members, such as by suicide bombing in public gathering areas (Cronin, 2003:CRS-3).
Unconventional weapons, information and expertise are more available due to
unaccounted-for former Soviet program assets (and possibly Iraqi assets). Finally,
terrorists have demonstrated “clear indications of interest in CBW,” such as when Osama
bin Laden “spoke of acquiring weapons of mass destruction being a ‘religious duty’” and
when al Qaeda dedicated a volume to producing CBW in the “Encyclopedia of Jihad”
(Cronin, 2003:CRS-3–CRS-4). USAMRIID’s Medical Management of Biological
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Casualties Handbook, commonly known as The Blue Book, aptly emphasizes to medical
providers that the reality of the threat should not be eschewed:
The threat of the use of biological weapons against U.S. military forces and
civilians is more acute than at any time in U.S. history, due to the widespread
availability of agents,…knowledge of production methodologies, and potential
dissemination devices. …Therefore, awareness of and preparedness for this
threat…is vital to our national security. (USAMRIID, 2005:12)
Anthrax Threat.
Anthrax is a zoonotic disease caused by Bacillus anthracis (BA), a gram-positive,
encapsulated, rod-shaped bacterium (USAMRIID, 2005:34; Heymann, 2004:20). BA
exists in the environment in a metabolically inactive spore form, which results when
nutrients are no longer available and which, unlike vegetative bacteria, lead to disease
upon bodily uptake (Liu and others, 2004:164). Layers form an “armored external shell,”
depicted in Figure 1, to protect the dormant bacterium in the core where the DNA is
preserved in a crystalline form for later reanimation by rehydration (Driks, 2003). While
active bacteria survive only briefly outside a host or for 24 hours in water (Inglesby and
others, 1999), the shell layers protect the spore from changes in humidity, temperature,
and pH, solar radiation, and other environmental conditions for decades or possibly
longer (Driks, 2003; Nicholson and others, 2000). BA spores germinate in a moist,
nutrient-rich environment like the human body; then the vegetative bacteria multiply
rapidly and cause anthrax disease in three unique forms: cutaneous, gastrointestinal, and
inhalational. Cutaneous anthrax occurs naturally among those working with animals or
their skins and has a mortality rate of less than 1% when treated (USAMRIID, 2005:36).
Insufficiently cooked meat from infected animals can cause rare cases of gastrointestinal
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Figure 1: Image of Bacillus anthracis by transmission electron
micrograph, showing cell division (A) and spore (B), left
(http://phil.cdc.gov/phil/bt.asp, photo ID #1813); and detail
of protective layers of a Bacillus spore, right (after Driks, 2003).

anthrax, which may result in pharyngeal ulcers or flu-like symptoms that can progress to
sepsis, resulting in a high mortality rate of 50%. Because spores can be dispersed in an
aerosol and because mortality may reach 85% with treatment, inhalational anthrax is the
“primary concern for intentional infection” in humans (USAMRIID, 2005:36-37). The
ability of a naturally occurring disease to cause such high morbidity and mortality is not
sufficient for a disease to be suitable for use as a biological warfare agent.
For application as a bio-warfare agent, a microorganism must also be able to be
mass produced, be stable enough to survive dissemination and the environment, and be
reasonably quick to cause disease or death; and the resultant disease must be preventable
or treatable (van Aken and Hammond, 2003:S58). The latter requirement applies
primarily to a nation state using bioagents against an enemy while not wanting to harm
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friendly forces. However, this requirement may not apply to modern terrorist groups
willing to sacrifice their own people and cross international borders to conduct the attack
far from home, where risk to their countrymen is reduced. Regarding the four other
requirements, “anthrax is of course the first choice because the causative agent, B
anthracis, fulfils nearly all of these specifications,” where the only specification not met
is in the ability to successfully treat anthrax victims “even several days after infection”
(van Aken and Hammond, 2003:S58). However, the 2001 anthrax letters did not have a
large quantity or a technical dissemination device; though a slow-acting pathogen, the
covert nature of the attacks resulted in delayed diagnosis and widespread fear. Law
enforcement, laboratories, and the military have embarked on developing greater defense
against such terrorist attacks.
In an effort to prioritize biodefense efforts, CDC led a risk assessment of sixteen
potential bioagents. Anthrax ranked higher than or equal to the other threat agents in five
of the six categories: infection rate, death rate, ease of production and dissemination,
public perception of risk, and need for specialized planning and logistical preparations.
Only smallpox was given higher priority due to a maximum score in the sixth category of
person-to-person transmissibility, whereas anthrax received a score of zero because
anthrax is not communicable between people (Rotz and others, 2002). A significant
number of lives would still be lost from a large scale anthrax attack. The dissemination
of 100 kg of weaponized anthrax outside a major metropolitan area such as Washington
D.C. could result in 130,000 to 3,000,000 deaths, where the numbers increase with
dissemination under more ideal weather conditions (OTA, 1993:54). Comparatively, the
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combined deaths from the World War II fire bombing of Tokyo, Japan and Dresden,
Germany was approximately 300,000 (OTA, 1993:2). A major anthrax attack would
equal or surpass the lethality of a one megaton (TNT-equivalent) hydrogen bomb and
dwarf a 1,000-kilogram sarin attack by three orders of magnitude (OTA, 1993:53). The
significant public health risks, when combined with increased threat, motivate
microbiological research to better elucidate the pathogenesis of inhalational anthrax and
to identify biomolecular mechanisms that may lead to advances in defense or treatment.

Background
Intracellular Signaling and Anthrax Toxin.
Just as some multicellular organisms use hormones to signal between organs and
systems to trigger growth, reproductive development, or metabolic changes, all eukaryotic
cells use highly-selective, internal signaling pathways to implement proliferation,
differentiation, movement, enzymatic changes, gene expression, or cell death
(Downward, 2001:759). This intracellular communication network is extremely
complicated, like a three-dimensional, interdependent and interactive spider web of
biochemical relationships spanning the cytoplasm between the cell membrane and the
nucleus. An alveolar macrophage (AM) is a highly phagocytic leukocyte serving as the
innate immune system’s first-responder, responsible for clearing the lungs of respired
particles, for recruiting other immune cells, and for triggering antibody (Ab) production
by stimulating lymphocytes (Dörger and Krombach, 2002:47). (Terms like leukocyte,
antibody and lymphocyte, as well as acronyms and abbreviations like AM, are defined in
Appendix A.) An AM is dependent on its internal molecular communication network for
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up- and down-regulating gene expression that mediates macrophage activation, defensive
factors, inflammation, and apoptosis, to facilitate combating an infection. Recent
research shows that interruption of critical signal transduction pathways changes the
macrophage and immune system responses and allows the survival of many pathogens:
Brucella abortus, a bacterium that causes brucellosis (Jarvis and others, 2002:7162);
Leishmania donovani, a parasitic protozoan that causes leishmaniasis (Junghae and
Raynes, 2002:5034); all three pathogenic Yersinia species of bacteria (Zhang and others,
2005:7946-7948); Plasmodium falciparum, the parasite that causes malaria (Zhu,
Krishnegowda and Gowda, 2005:8623); and the biological threat agent Bacillus anthracis
(Park and others, 2002:2048).
In inhalational anthrax, aerosolized spores are respired into the alveoli of the
lungs, where vigorously phagocytic alveolar macrophages (AM) rapidly ingest the foreign
particles. Normally the key executor of early bactericidal action, the AM instead serves
as the primary site of the BA spore’s germination into a vegetative bacterium (GuidiRontani and others, 1999:13). The reanimated bacterium must quickly begin to produce
anthrax toxin (AT) to suppress the macrophage’s production of cytotoxic reactive oxygen
intermediates and of cytokines, proteins that would recruit additional innate and adaptive
immune cells to the site of infection (Guidi-Rontani, 2001:935; Chakrabarty and others,
2006:4430). AT is composed of three parts: protective antigen (PA), lethal factor (LF)
and edema factor (EF). The binding of a factor with PA results in the correlating toxin,
lethal toxin (LF + PA = LT) or edema toxin (EF + PA = ET). PA binds to receptors on
cell membranes and forms a complex with LF and EF; the complex is then endocytosed
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into the cytosol (Park and others, 2002:2048; Singh and others, 1999:1857-1858). ET
increases the cytoplasmic concentration of cyclic adenosine monophosphate (cAMP),
which causes the edema (Leppla, 1991:3164). The critical mechanism is the interruption
of the cell’s signal network when LF, a proteinase, cleaves enzymes in one of the most
common (and most frequently studied) signal path families, the mitogen-activated protein
kinase (MAPK) cascade. By eliminating intermediate enzymes in a series of enzyme
activations, LF prevents downstream enzymes’ activation (the signal output), inhibiting
subsequent nuclear transcriptions required for normal immune response and facilitating
programmed cell death (Park and others, 2002:2048). Decades of in vitro and in vivo
studies were supported by a study in which mice were injected with BA clones able to
produce only two of the three toxin components; the results “strongly suggest that LF in
combination with PA is the key virulence factor” (Pezard, 1991:3476). However, in vivo
exposure to LT alone is not equivalent to inhalational anthrax due to the difference in
immune response mechanisms for injected toxin and inhaled spores.
The macrophage, called a Trojan horse in many journal articles, plays a prominent
role in anthrax pathogenesis. Macrophages transport BA from the alveoli, through the
mucosal layer that typically bars direct bacterial penetration, and to the mediastinal lymph
nodes between the lungs (Guidi-Rontani, 2002:407). The bacteria proliferate, cause
lymphadenopathy for which chest a x-ray will show characteristic widened mediastinum
(see Figure 2), and cross into the bloodstream, causing respiratory distress, septicemia,
shock, and death (USAMRIID, 2005:37). The macrophage has been implicated in
toxicity even in the absence of bacteria. For undetermined reasons, mice depleted of their
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Figure 2: Chest radiograph of inhalational anthrax victim, 22 hours before death
(modified from CDC, http://phil.cdc.gov/phil/bt.asp, photo ID #1118)

macrophages before injection with a lethal dose of LT were resistant to the toxin (Hanna
and others, 1993:10199). By inhibiting MAPK signaling, BA turns the macrophage’s
activation signal into “a trigger of rapid cell death,” meaning no active macrophages
“alert the remainder of the immune system to the presence of the pathogen” (Park and
others, 2002:2051). An understanding of macrophage MAPK inhibition by LF and the
resultant effects is critical to advancing anthrax treatment and biodefense research. The
dynamic nature of the host-pathogen system demands a dynamic investigation method.
Systems Biology.
While advances in genomic research have permitted the cataloguing and analysis
of a multitude of cellular components, laboratories are frequently resource limited and
thus “concentrate on models that are part of a larger whole” or, in signal transduction,
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“individual pathways and usually only a subset of proteins for any particular experimental
set-up” (Cho and Wolkenhauer, 2003:1504). Experimental scope is also constrained to
facilitate drawing conclusions within the highly variable intracellular environment.
Researchers often only investigate the function of individual proteins, genes, or other
biomolecules and therefore reveal only associations or covariant relationships while
failing to determine causality (Cho and Wolkenhauer, 2003:1503). Volumes of
fragmented data do not readily provide understanding of behavior, because in reality:
•

One stimulus may activate multiple pathways and cause multiple responses;

•

Redundancies exist (so inhibitors may not fully have the intended effect);

•

Positive and negative feedback loops are embedded throughout signal pathways;

•

Pathway components’ kinetic relationships are often non-linear;

•

Cells constantly sense and respond to multiple stimuli simultaneously; and

•

Signal transduction is both time and space dependent.

“A different approach is necessary to identify causal entailment directly from
experimental data”; “a signal- and systems-oriented approach is the way forward in the
understanding of gene expression and regulation” (Cho and Wolkenhauer, 2003:1503).
An emerging discipline of mathematical modeling known as systems biology (SB) blends
microbiology and engineering to bridge the gap between existing, piecemeal experimental
data and the “relationships…that give rise to cause and effect in living systems” (Cho and
Wolkenhauer, 2003:1503). The goal is a more holistic view of how cells function and
what gives rise to behavior. SB models are used to validate current understanding,
indentify incongruities, predict behavior, “reveal features not easily recognizable by
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examining the constituent parts,” and “suggest experimentally testable hypothesis” (You,
2004:169,175). Even highly simplified models based on significant assumptions can be
useful, even if unable to predict behavior, by guiding experimental design and by helping
“to identify which variables to measure and why” (Cho and Wolkenhauer, 2003:1509).
Although “host-pathogen systems biology is still in its infancy” (Forst, 2006:220),
cost reduction and acceleration of therapy and drug discovery has led researchers to use
the paradigm to examine signal inhibition for: Group A Streptococcus (Musser and
DeLeo, 2005); Plasmodium parasites that cause murine (rodent) malaria (Fraunholz,
2005); Helicobacter pylori, the bacteria that cause ulcers (Franke and others, 2008); and
macrophage activation by an endotoxin (Tegner and others, 2006). In vivo and in vitro
MAPK research has already been integrated into ‘dry lab’ experiments performed in
silico, a term coined to describe the computer chips in which the computations occur.
However, based on review of the literature, it is believed that no host-pathogen SB study
has examined the signal interactions of a macrophage and Bacillus anthracis or its toxin.

Research Objectives
As expressed by various authors in the SB discipline, even a simple model may
prove useful for predicting intracellular interactions and, therefore, for establishing
hypotheses toward tailored laboratory investigation. The purpose of this research is to
develop a model that depicts the effect of anthrax lethal factor on the macrophage MAPK
signaling pathway by comparison to in vitro data for macrophage cell death. The model
will also provide estimates of the MAPKK cleavage reaction rate constant. Published and
fully parameterized signaling models are used as the model foundation to which the
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equations for the host-pathogen interaction are added. A basic model of the key hostpathogen intracellular activities is the first step in developing more detailed cell signaling
models that may include combined toxin effects, multiple signal path effects, gene
transcription and cytokine secretion, or toxin effects in other immune and non-immune
cells. Models of increasing scale, such as macrophage migration to the lymph nodes or
system-level immune response, may also follow. Ultimately, though a human infection
model is “still in the realm of science fiction” (Forst, 2006:227), an airborne spore
concentration-dependent dose-response model is needed for a more accurate health risk
assessment following an anthrax attack. Modeling may also progress to drug discovery or
investigation of prophylaxis options. This initial model of the root pathologic mechanism
should aid in designing experiments that will facilitate advancing the model.

Scope and Limitations
The models developed here are specific to the macrophage and do not consider
other leukocytes, evasion of the immune response, or systemic disease. The models are
limited to the interactions of lethal factor with the MAPK cascade. The models exclude
the potential effects of edema factor and protective antigen and do not address toxin
interaction with other pathways as possible contributions to virulence and pathogenesis.
Each model investigated here is assumed to be an accurate representation of the
underlying data, referenced in the respective work, and to be properly parameterized. The
cascade kinetics and constants are assumed to be applicable to the activated macrophage,
and those values are assumed to be unaffected by phagocytosis of B anthracis by the
macrophage. The cleavage of MAPK signal intermediates by LF is assumed to be
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catalytic and first-order. Further, despite the existence of a number of molecular
variations (isoforms), target intermediates are treated as a group because LF reacts with
nearly all forms at the same level in the cascade. Finally, the active MAPK concentration
is assumed to be linearly related to the cell viability data from “Differential susceptibility
of macrophage cell lines to Bacillus anthracis-Vollum 1B,” published in Toxicology in
Vitro by Gutting et al in 2005, in which macrophage cells were cultured in tandem with a
LT-producing strain of BA. The limitations and assumptions collectively result in
limitations on the application of the models. The models cannot be used as predictive
tools for detailed cell or system response, for cells other than macrophages, or as doseresponse models. While the models are expected to perform qualitatively as
representations of system behavior, the limited cell viability data and inability to
accomplish stronger validation tests also result in limited confidence in quantitative
output of the models.
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II. Literature Review

Chapter Overview
For over a century Bacillus anthracis (BA), the causative bacterial agent leading
to anthrax disease, has been to microbiologists what the fruit fly has been to traditional
(macro) biologists. Before biologists observed inheritance of genetic traits in fruit flies,
microbiologists were developing theories on pathogenic disease transmission using BA.
Research has since been conducted into the effects of anthrax on numerous animals,
immune cell types, epithelial cells, and even nerve cells. The components of anthrax
toxin have been purified and used for in vivo and in vitro research for many years. More
recently, the effect of anthrax toxin on immune cell MAPK signaling has been
investigated in vitro and in vivo. This literature review begins by providing more detail
on the MAPK signaling enzyme family and the MAPK-mediated cellular immune
response. The topics of pathogenesis and biomolecular effects of inhalational anthrax on
the immune cells follow. Finally, the systems biology modeling approach is introduced,
and the selection of published MAPK cascade models built upon for this analysis will be
covered with respect to their unique attributes.

Signaling and Immunity
Mitogen-Activated Protein Kinases.
It is necessary to simplify signal transduction from “the impenetrable soup of
acronyms that it might at first appear to be” into key functional roles or sequential steps
seen in most signaling pathways (Downward, 2001:759). First, as a form of sensory
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perception that allows information about the extracellular environment to be internalized,
cell membrane surface receptors bind with specialized stimulus molecules called ligands
on the external side of the membrane, often resulting in changes in structure or
orientation of the surface receptor molecules. Second, a change at the intracellular end of
the receptors initiates the cell’s internal signaling, commonly by activation of enzymes.
Third, the active enzymes recognize certain proteins; an enzyme will bind with a target
protein to form a complex or will catalytically activate other proteinaceous enzymes. A
series of enzyme activations, known as a cascade, may occur. Finally, whether by one or
many steps in series, the signal’s chain reaction commonly ends with a product protein
entering the nucleus and altering gene transcription activities by either activating or
inhibiting proteins known as transcription factors that mediate generation of messenger
ribonucleic acid (mRNA), a protein synthesis template that facilitates information transfer
from the DNA to the cytoplasm (Downward, 2001:759-760). Signal strength can be
affected by interaction of enzymes with upstream mediators in the same reaction chain,
resulting in either a positive or negative feedback loop. “Some pathways work as on/off
switches”: a signal does not complete the path from surface receptor to transcription
factor unless the intensity of the input signal at the surface receptors reaches a threshold
level, at which point “positive feedback results in full activation of downstream targets”
(Downward, 2001:762). Kinases are perhaps the most common and, therefore, the most
represented enzymatic messengers in research.
A kinase is an enzyme which transfers a phosphate group from a donor such as
adenosine triphosphate (ATP), the key supplier of energy to cells for various biochemical
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processes, to a target molecule. This process, known as phosphorylation, has the effect of
either activating or inhibiting the receiving target. Naming of a kinase is based on the
substrate: a protein kinase targets a protein for phosphorylation; similarly, a kinase kinase
is a kinase that phosphorylates another kinase. The term mitogen-activated protein kinase
(MAPK) was originally the name for a specific phosphoprotein in the early 1980s, but
research has since revealed dozens of enzymes with similar structure and biological
functions (Pearson and others, 2002:154). A mitogen is an extracellular stimulus that
signals for the initiation of mitosis; however, just as multiple MAPKs with different
terminal functions have been identified, various cytokines (non-antibody proteins released
as intercellular mediators of immune response to an antigen), thermal stress, and osmotic
shock have been identified as MAPK cascade stimuli (Pearson and others, 2002:158).
MAPK thus became a term for a family of enzymes and then, after analysis showed
multiple isoforms of each MAPK type, a “superfamily” (Nick and others, 2001). “All
eukaryotic cells possess multiple MAPK pathways, which coordinately regulate diverse
cellular activities running the gamut from gene expression, mitosis, and metabolism to
motility, survival and apoptosis, and differentiation” (Roux and Blenis, 2004:321).
The biochemical stages that apply to each MAPK pathway can also be simplified
as seen on the left half of Figure 3. At the cell membrane, a MAP kinase kinase kinase
(MAPKKK, also herein denoted as generic enzyme E3 for simplicity) is activated by cell
surface receptors in response to external stimuli. MAPKKKs in turn activate a MAP
kinase kinase (MAPKK, or E2) by phosphorylating two amino acid sites via two separate
reactions. Finally, MAPK (E1) is also activated by MAPKKs by two reactions (Roux and
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Figure 3: Steps of the MAPK cascade (modified from Roux & Blenis, 2004)

Blenis, 2004:321). On the right, Figure 3 depicts the three main subfamilies of terminal
MAPKs: extracellular signal-regulating kinase (ERK), p38, and c-Jun N-terminal kinases
(JNK). Multiple isoforms exist within each of the three main modules and are typically
designated by a number, as in ERK1, or with a Greek character, such as p38α. As the
final tier in the cascade (not shown in the figure), the active MAPKs either activate
regulatory biomolecules in the cytoplasm or migrate into the nucleus to activate
transcription factors for production of various isoform-dependent cytokines. Some of the
cytokines are specialized chemoattractants called chemokines that are released during
inflammation to mobilize and activate phagocytes and lymphocytes. Table 1 lists some of
the cellular sources and immune functions of some cytokines related to macrophages.
Blocking a signal through inhibition or reaction with MAPK or an upstream kinase may
disrupt intracellular homeostasis or regulatory mechanisms through excess or insufficient
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Table 1: Cytokine sources and immunoregulatory functions
Cytokine
Source(s)
Physiologic Actions
Interleukin-1
Macrophages
Activation and proliferation of T cells
(IL-1)
B cells
Proinflammatory
Many non-immune cells Induces fever and acute-phase proteins
Induces synthesis of IL-8 and tumor
necrosis factor-alpha (TNF-α)
IL-6
Macrophages
Enhances B cell differentiation and Ab
Activated T cells
secretion
B cells
Proinflammatory
Fibroblasts
Proliferation of T cells, increased IL-2
Endothelial cells
receptor expression
IL-8
Macrophages
Activation and chemotaxis of
Platelets
monocytes, neutrophils, and T cells
Natural killer (NK) cells Proinflammatory
Endothelial cells
IL-10
Macrophages
Inhibits macrophage cytolytic activity
T cells
and activation of T cells
B cells
Inhibits cytokines in helper T cells
Enhances cytotoxic T cell activity
Enhances activated B cell proliferation
Anti-inflammatory
IL-12
Macrophages
NK cell proliferation and cytolytic
B cells
action
Cytotoxic T cell activation, proliferation
Stimulates production of IFN-γ
Proliferation of activated T cells
IL-15
Activated monocytes
NK cell activation
Macrophages
T cell proliferation
Many non-immune cells
Interferon-α/β
Leukocytes
Induction of class I expression
(IFN-α/β)
Epithelial cells
Antiviral activity
Fibroblasts
Stimulation of NK cells
Tumor necrosis Macrophages
Induces inflammatory cytokines
factor-α
Lymphocytes
Increases vascular permeability
(TNF-α) and
Activates macrophages and neutrophils
lymphotoxin
Tumor necrosis action
(TNF-β)
Primary mediator of septic shock
Transforming
Macrophages
Enhances macrophage chemotaxis
growth factor-β
Enhances wound healing
(TGF-β)
Inhibits T and B cell proliferation
Inhibits macrophage cytokine synthesis
Inhibits Ab secretion
(adapted from Klaassen and Watkins, 2003: 181)
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cytokine production, which in turn can lead to apoptosis, necrosis, or a failure to respond
to exoteric substances.
A pathogen that can alter gene transcription can thus alter the immune cell’s
response. One study analyzed five different bacteria that were phagocytosed by
neutrophils, which are highly microbicidal phagocytes that constitute the largest fraction
of leukocytes, also known as polymorphonuclear (PMN) leukocytes, granulocytes or
professional antigen presenting cells (APC). The neutrophils subsequently experienced
up- and down-regulation of common sets of genes leading “to resolution of bacterial
infection” followed by apoptosis (Kobayashi and others, 2003:10951). Phagocytosis of a
sixth bacterium, Streptococcus pyogenes, affected transcription of the same gene sets in
the same manner as the other five, but also simultaneously down-regulated 21 additional
genes that control immunoregulatory factors known as interferons (IFN). Neutrophil
apoptosis was highly accelerated and then, unlike the other five, followed by necrosis.
The change in gene transcription uniquely “alters the apoptosis differentiation program in
neutrophils, resulting in pathogen survival and disease” (Kobayashi and others,
2003:10951). Though these effects on gene expression may not have been caused by
MAPK signal inhibition, the MAPK cascade is responsible for regulating the expression
of cytokines involved in cellular and systemic immune response.
MAPKs and Immunity.
The cytokine tumor necrosis factor-alpha (TNF-α) is a “proinflammatory cytokine
that acts as a mediator of host defense against…infection and is principally expressed in
macrophages” at up to 10,000 times normal levels upon bacterial challenge (Zhu and
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others, 2000:6349). TNF-α regulates immune cell inflammatory response and apoptosis,
but release of TNF-α is first regulated through MAPK signaling. In an investigation of
the relationship between the MAPK signal, TNF-α, and immunity, murine alveolar
macrophages and neutrophils were treated with “the most highly selective and potent
inhibitor of p38 MAPK described to date” and then stimulated by lipopolysaccharide
(LPS), an endotoxin derived from Gram-negative bacteria and commonly used as a
macrophage activator (Nick and others, 2000:2152). “Rapid accumulation of neutrophils
to the lung in response to a proinflammatory stimulus is one of the first recognizable
events in the pathogenesis of many pulmonary diseases” (Nick and others, 2000:2151).
Inhibition of p38 in vitro blocked LPS-induced secretion of TNF-α and the murinehomologues of IL-8, a neutrophil-specific chemoattractant; and administration of the p38
inhibitor by gastric intubation resulted in a 50% drop in TNF-α secretion and failure of
the neutrophils to migrate to the lungs in vivo (Nick and others, 2000:2152). Neutrophil
recruitment may have failed in vivo because the p38-inhibited neutrophils could not
mobilize toward the chemoattractant, because the p38-inhibited macrophages and
epithelial cells could not produce adequate chemoattractant, or due to a combination of
both. Regardless, the results show that MAPK inhibition causes the immune cells and
system to respond in a significantly reduced capacity.
MAPK activation and inhibition has been studied for a number of diseases, as was
briefly summarized in the introduction. MAPK cascades have been investigated by
neurologists searching for the molecular basis of memory formation (Sharma and Carew,
2004) and have even been researched in heavy metal toxicity and thermal stress response
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in mollusks (Kefaloyianni and others, 2005). The cytokine-inducing roles ERK, p38 and
JNK pathways were examined in murine bone-marrow derived macrophages exposed to
Plasmodium falciparum, a parasite that causes malaria in rodents. In vitro testing with
targeted inhibitors revealed that all three pathways are activated by the pathogen and that
each correlates to the expression of a different set of cytokines. A demonstration of
specificity and redundancy between pathways occurs between the two JNK isoforms.
JNK1 and JNK2 both trigger secretion of TNF-α by macrophages stimulated with the
parasite’s proinflammatory factors, but only activation of the JNK2 MAPK path results in
interleukin-12 (IL-12) production (Zhu, Krishnegowda and Gowda, 2004:8624-8625).
Similar to some anthrax studies, rapid apoptosis of macrophages has been found to
facilitate survival of Yersinia pseudotuberculosis. A protease (an enzyme that
catalytically breaks down proteins, also called a proteinase) associated with the pathogen
inhibits activation of the JNK, p38, and ERK pathways (Zhang and others, 2005:7947).
The result is a lack of enzyme-mediated gene expression of anti-apoptotic factors that
would allow the macrophage time to respond to the ingested pathogen, and instead the
macrophage experiences rapid apoptosis. As mentioned above, anthrax LF is also a
protease and inhibits nearly all MAPK cascades. Interestingly, another study of MAPK
signaling, in relation to the disease leishmaniasis, showed that “a specific inhibitor of
p38…increases Leishmania donovani survival in human peripheral blood mononuclear
macrophages” and that treatment with a p38 and JNK activator actually reduced parasite
survival while decreasing the macrophage infection rate by 50% (Junghae and Raynes,
2002:5026). Hijacking the macrophage’s internal communication network, and often
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times the MAPK cascades specifically, presents pathogenic microorganisms the
opportunity to breach the barrier of early immune response and go on to cause systemic
infection. Yet the reverse is also true: “MAPK activation may have a potential
therapeutic value” (Junghae and Raynes, 2002:5026).
Differential Responses.
Despite the findings of Nick et al on MAPK-mediated TNF release in relation to
neutrophil recruitment, the unique roles of the three primary MAPK groups in cytokine
production are still unclear. A 1999 article in the Journal of Surgical Research,
“Macrophage TNF Secretion in Endotoxin Tolerance: Role of SAPK, p38, and MAPK”
by Kraatz et al, investigated the effects of repeated stimulation and appears to agree with
the findings of Nick et al. Testing peritoneal murine macrophages pre-treated with LPS
24 hours prior to LPS activation and analysis, Kraatz et al indicate that LPS activates
stress-activated protein kinase (SAPK, called JNK here), p38, and MAPK (called ERK
here); that “partial blockade of p38 alone results in decreased TNF” in a dose-response
relationship; and that, though the role of ERK is unclear, JNK does not appear to be
required for TNF-α release (Kraatz and others, 1999:163). However, in the June 2000
edition of The Journal of Immunology, Zhu et al published “Regulation of TNF
Expression by Multiple Mitogen-Activated Protein Kinase Pathways,” in which they
found that LPS activates all three main MAPK modules in the RAW264.7 macrophage
cell line, and that all three are necessary for full TNF-α production. A similar study with
the same cell line only identified p38 and JNK as being activated by LPS stimulation; that
study also found that treatment of cells to dephosphorylate p38 and JNK resulted in “a
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substantial decrease in TNF-α production” without a significant decrease in active ERK
(Chen and others, 2002:6414). In vitro analysis of Group B Streptococci (GBS)
activation of monocytes, which are macrophage precursors, resulted in a dose-dependent
activation of all three main MAPK subgroups; however, MAPK activation by GBS was
more delayed and of longer duration that LPS-induced MAPK activation. The effect of
JNK inhibition was not tested, but inhibiting either the ERK or p38 MAPK pathways did
partially inhibit TNF-α expression. The simultaneous inhibition of ERK and p38 was
required to completely block TNF-α release (Mancuso and others, 2002:1401-1402). The
p38 inhibitor used by Nick et al blocked TNF-α release effectively, like anthrax LT does,
whereas the p38-specific inhibitor used by Park et al in “Macrophage Apoptosis by
Anthrax Lethal Factor Through p38 MAP Kinase Inhibition,” published in Science in
2002, did not prevent TNF secretion (Park and others, 2002:2050), and the p38 inhibitor
used on the GPS-activated monocytes caused significant but partial TNF-α expression.
Interestingly, Park et al and Kraatz et al used the same inhibitor (SB202190) but obtained
very conflicting results, with the former finding no TNF-α inhibition and the latter finding
dose-dependent inhibition (supporting Nick et al). One possibility is that repeated
stimulation affects the macrophages’ response; but the underlying biological variation
among cells and animals is generally known to make a difference in cell response.
Bonni et al described the pro-survival, anti-apoptotic functions of ERK in “Cell
survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and
–Independent Mechanisms” from the 12 November 1999 issue of Science. When
activated in neurons, ERK “promotes cell survival by a dual mechanism” in which ERK
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phosphorylates one pro-apoptotic protein, deactivating it and thereby suppressing
apoptosis, and phosphorylates one anti-apoptotic transcription factor, suppression of
which “triggers apoptosis” (Bonni and others, 1999:1358,1361). Logically, though ERK
may not directly affect TNF secretion, inhibition of the ERK pathway would, in turn,
result in inhibition of the anti-apoptotic factor and lead to apoptosis as seen in
macrophages treated with LF (Park and others, 2002). However, Bonni et al studied
neurons, not macrophages. Park et al specify that LF inhibits both the p38 and JNK
MAPK paths, the two paths associated with inflammatory response and apoptosis
(Herlaar and Brown, 1999:439); those results represent anthrax LF treatment of the
J774A.1 cell line and bone marrow-derived macrophages. In “MAP kinase activation in
macrophages” from the January 2001 Journal of Leukocyte Biology, Krishna Rao states
that “the activation of MAPKs seems to be different in cell lines compared with primary
cells,” or even between macrophages from different tissues. This is a possible reason for
the differential susceptibilities observed in different species. Rao recommends against
extrapolation from cell lines, such as RAW264.7, to primary cells, such as the human AM
(Krishna Rao, 2001:3). However, data for signal transduction and cytokine secretion by
the human alveolar macrophage are rare.
Each investigator used a different experimental set-up. Nick et al used murine
alveolar macrophages, while Kraatz et al used murine peritoneal macrophages and seems
to support Nick et al. Park et al and Zhu et al studied cell lines and conflicted with Nick
et al and Kraatz et al. It is possible that Park’s p38 inhibitor did not successfully inhibit
all p38 isoforms (Nick et al claimed theirs to be the “most selective and potent” to date);
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or Nick’s inhibitor may also inhibit redundant MAPK pathways, such as JNK (nearly
three years later, Park’s may be more selective), leading to TNF-α gene expression. Park
et al and Kraatz et al used the same inhibitor and may have observed different effects due
solely to the difference between cell types. Factors such as repeat stimulation used by
Kraatz et al or simple methods of treatment may have also influenced the results. Zhu et
al and Chen et al stimulated the same macrophage cell line using LPS, but only one found
that ERK was activated. “All three MAPKs have been shown to undergo activation in
several macrophage cell types using a variety of stimuli, [and] the response appears to be
context-specific” (Krishna Rao, 2001:7). Anthrax lethal factor has been widely accepted
as the main virulence factor of BA, and though the complete mechanism is not
understood, the main cytotoxic activity is the non-selective cleavage of nearly all
MAPKK isoforms. Adding that all terminal MAPKs have the potential to affect human
AM microbicidal response, all forms of MAPKs should be considered when modeling
cell response.

Anthrax Evasion of Immune Response
Inhalational anthrax in the U.S. has historically had a mortality rate of over 85%,
but many cases included in this figure occurred prior to development of modern medical
facilities and antibiotics available during the intentional 2001 postal attacks, which
resulted in five deaths among the eleven inhalational cases, or a 45% mortality rate
(USAMRIID, 2005:37). The majority of natural inhalational infections during the
twentieth century were from occupational activities, occurring among wool sorters in
textile mills, goat hide and hair processing workers, and tannery workers (Inglesby and
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others, 1999:1736). Unique from the long-recognized cutaneous form, inhalational
anthrax was even known historically as Woolsorters’ disease due to its prevalence among
this high-risk population (USAMRIID, 2005:36). As described in the introduction,
respirable spores are quickly bound and phagocytosed by AMs, which begin transferring
the spores from the lung to the mediastinal lymph nodes. Despite the microbicidal
attacks of the leukocytes, BA spores may survive for up to 60 days before they germinate
into vegetative bacteria and may possibly multiply inside the macrophages (Chakrabarty
and others, 2006:4430; Park and others, 2002:2048; Guidi-Rontani and others, 1999:13).
In the lymph nodes, the vegetative bacteria proliferate and produce anthrax toxin (AT),
“leading to hemorrhage, edema, and necrosis” in the infected tissue (Inglesby and others,
1999:1737-1738; Heymann, 2004:20-22). After an incubation period generally lasting
one to six days, a generic illness manifests with flu-like symptoms of fever, fatigue,
headache, mild cough, and nausea. A correct diagnosis is further complicated due to an
examination of the lungs typically being normal in this early stage. However, once the
disease progresses victims exhibit the characteristic mediastinal widening (Figure 2),
often also with pleural effusion (USAMRIID, 2005:37). After approximately two to five
days, the non-specific symptoms may improve briefly only to be followed abruptly by
severe respiratory distress. “Septicemia, shock and death usually follow within 24-36
hours after onset of respiratory distress unless dramatic life-saving efforts are initiated”
(USAMRIID, 2005:37). In Figure 2, a radiograph from the CDC Public Health Image
Library, the white areas indicated by the arrows show the classic signs of mediastinal
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widening and pleural effusion in an inhalational anthrax victim less than a day before
succumbing to the systemic bacterial infection and toxins.
Instead of preventing the infection, macrophages play the critical role of facilitator
by allowing a BA bacterium to evade the immune response and progress to a systemic,
lethal disease. The ability of BA to effectively subvert a macrophage’s normal protein,
enzyme or genome functions to evade the cellular immune response are not unique to the
macrophage. BA also exerts MAPK pathway inhibition in dendritic cells, vigorous
phagocytes and antigen presenting cells (APC) like the macrophage but with a smaller
population, better ability to migrate to the lymph nodes, and a more potent T-cell priming
ability; in T-cells, adaptive immune lymphocytes that promote the overall immune
response, kill exogenic microorganisms through specialized antigen recognition, and
provide long-term immunity; and B-cells, adaptive lymphocytes that produce antibodies
in response to antigens (Baldari and others, 2006:437-439).
•

In a dendritic cell (DC), anthrax toxin up- and down-regulates the production
of different interleukins, which are cytokines secreted to mediate lymphocyte
response, and inhibits the production of TNF-α (Tournier and others,
2005:4938-4940). When MAPK signaling is disrupted by LT, DCs “do not
upregulate co-stimulatory molecules, secrete greatly diminished amounts of
proinflammatory cytokines, and do not effectively stimulate antigen-specific T
cells in vivo” (Agrawal, 2003:329). The DC response is effectively dampened
such that it is unable to respond to stimuli.
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•

Two studies recently showed that T-cells fail to produce IL-2 due to LT
inhibition of MAPK signals. One study found that LT caused inhibition of Tcell proliferation; LT was so selective in its attack on MAPK intermediates
that the researchers even proposed LT be used as a MAPK signal inhibitor in
investigating other signal pathways (Fang and others, 2005:4970-4971).
Using a mouse (murine) model in vitro, the second T-cell study showed that
IL-2 inhibition directly resulted in failure of cell activation and identified two
of the three main MAPK sub-families, which are discussed below, as the
primary targets of the toxin (Comer and others, 2005:8278-8279).

•

“Anthrax LT treatment causes severe B cell dysfunction” at “picomolar
concentrations in vivo and sublethal doses in vitro”; LT causes “markedly
diminished capacity to proliferate and produce” immunoglobulin-M (IgM) in
response to stimuli (Fang and others, 2006:6155).

While recent work has shown that DCs also transport anthrax spores to the lymph nodes
(Cleret, 2007:7994), activated AMs have been shown to inhibit the migration of DCs to
the lung (Jakubzick, 2006:3582) and the antigen presenting function of naïve and mature
resident pulmonary DCs (Holt and others, 1993:404). Further, analysis has shown that a
threshold particle exposure must first be reached to induce phagocytosis of particulates by
pulmonary DCs; and AMs that engulf respired particulates still outnumber DCs by more
than two orders of magnitude (Jakubzick, 2006:3578,3581). While macrophages may be
less efficient at transport to the lymph nodes, DCs are outnumbered and depend on
macrophages for chemotaxis and activation. The focus in anthrax pathogenesis research
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centers on the effects of LT or LF on macrophage MAPK signal transduction because
macrophages fill this significant role in the early response to and transportation of the
inhaled spores and in initiating the full innate and adaptive immune response.
“In order to understand how anthrax evades the innate immune response and to
gain insight into why inhalation anthrax is so lethal, it is critical to dissect the complex
interactions between B anthracis and macrophages” (Banks and others, 2005:1180). The
article by Park et al reported on the “causal relation between dismantling of MAPK
signaling and LT-mediated toxicity” (Park, 2002:2048). Macrophage cell lines were
treated with LPS or with lipoteic acids, an activator derived from Gram-positive bacteria.
Both activators induce multiple MAPK pathways, including the three main sub-families:
ERK, p38 and JNK. Protective antigen was added to facilitate LF entry into the cells. At
a 200 ng/mL concentration, LF caused rapid apoptosis in LPS-activated macrophages and
no observed apoptosis in non-activated cells. At the same concentration, LF was also
found to inhibit p38 and JNK1 MAPKs. “Using inhibitors that are selective for each
MAPK cascade,” a portion of this LT-induced inhibition was simulated for each of the
three MAPK modules individually (Park and others, 2002:2049). The p38 inhibitor was
the only one to cause LPS-activated macrophage apoptosis similar to LF. Macrophage
mutants were then designed to express p38-activating MAPKKs (E2) that are not
recognized for cleavage by LF. LPS-treatment of these mutants showed “considerable
resistance to LF-induced apoptosis” but no resistance to the p38-specific inhibitor,
leading to the conclusion that apoptosis following introduction of lethal toxin is
dependent the ability of the macrophage to produce p38 (Park and others, 2002: 2049).
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Polymerase chain reaction (PCR) DNA analysis determined that p38 MAPK inhibition by
both LT and the p38-specific inhibitor resulted in failure of the macrophages to express
genes for IL-1 isoforms α and β. IL-1 cytokines trigger production of IL-2 in T cells as
well as the general inflammatory response. Further, PCR revealed that LT suppressed
TNF-α gene transcription and, unlike Kraatz et all and Nick et al, that the p38-specific
inhibitor did not suppress expression of TNF-α genes (Park and others, 2002:2050). The
majority of studies indicate that TNF-α is the product of multiple MAPK pathways, of
which p38 is only one, but all of which are inhibited by LT. Further, in tests that were
able to insert LF into cells without the use of PA, LF alone “was cytolytic for the
sensitive macrophages while resistant cells were unaffected,” leading to the conclusion
that “lethal factor by itself possesses the toxic activity of lethal toxin” (Friedlander and
others, 1993:245). Echoing most current literature, Park and others conclude that
Bacillus anthracis uses MAPK inhibition to manipulate a macrophage activation signal
into “a trigger of rapid cell death,” thereby preventing “the secretion of chemokines and
cytokines that alert the remainder of the immune system to the presence of the pathogen”
and releasing vegetative bacteria into the lymph and circulatory systems to proliferate and
cause systemic toxigenic effects and bacteremia (Park and others, 2002:2051).
The biochemical mechanism by which the MAPK cascades are inhibited is very
well documented in the literature. LF is a protease, or proteinase, that cleaves the
MAPKK (E2) near the amino-terminus of the protein with such catalytic efficiency that
“proteolysis of MAPKK1 was observed within 15 min with as little as 2 ng of LF per
200 ng MAPKK1” (Duesbery and Vande Woude, 1999:291). The MAPK/ERK kinases
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(MEKs) MEK1 and MEK2, which activate the ERK family; MEK3 and MEK6, which
activate p38 MAPKs; and MEK4 and MEK7, which activate JNK isoforms, have all been
confirmed as targets of the proteolytic action of LF (Pellizzari and others, 1999:199;
Vitale and others, 2000:739; Bardwell and others, 2004:574-575). Interestingly, two
potential cleavage sites exist for MEK4 and MEK7, one of which resembles but is not a
docking site for MAPK recognition and phosphorylation (Bardwell and others,
2004:576). The regions of MAPKKs recognized by LF have even been identified via
testing cells with engineered point mutations in MEK1 and MEK6. The cleavage of the
MEK1 “was found to reduce not only the affinity of MEK1 for its substrate…but also its
intrinsic kinase activity” (Chopra and others, 2003:9402). The E1-level terminal kinases
that regulate cell function and cytokine expression can no longer be phosphorylated
because lethal factor’s “removal of the amino terminus of MAPKKs eliminates the
'docking site' involved in the specific interaction with MAPKs” (Vitale and others,
1998:706). The strong evidence of LF-induced apoptosis has led to research on the use of
LF as a therapeutic agent. A study funded by the National Cancer Institute showed
melanoma cell apoptosis via treatment with both LT and MAPKK inhibitors and even
documented “tumor regression without apparent side effects” in mice (Koo and others,
2002:3052). The literature is thus found to support this effort of developing an initial
host-pathogen systems biology model based on MAPKK cleavage by anthrax LF
resulting in alveolar macrophage apoptosis.
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System Biology and the Host-Pathogen Model
“The emergence of systems biology signals a shift of focus away from molecular
characterization of the components in the cell to an understanding of functional activity
through the interactions in molecular dynamics” (Cho and Wolkenhauer, 2003:1503).
Though systems biology (SB) literature has increased significantly in the last decade, the
application to the doubly-dynamic host-pathogen system is still a nascent, novel approach
within the microbiology and systems disciplines (Musser and DeLeo, 2005:1461).
However, recognizing the uniqueness of modeling infectious diseases, the term hostpathogen systems biology already appears to be well established in the SB community.
Of course, though traditional microbiological studies of pathogens have occurred for
more than a century, much more modern laboratory research on all the relevant
biomolecular components and their individual relationships is still necessary to provide
an adequate aggregate of data for increasingly detailed computational biological models.
Until then, a number of assumptions must be made to turn disjointed, limited and
possibly disparate data on molecular mechanisms into testable predictions of system
(organism) behavior. In a 2005 review from the American Journal of Pathology titled
“Toward a Genome-Wide Systems Biology Analysis of Host-Pathogen Interaction in
Group A Streptoccoccus,” Musser and DeLeo state:
Analysis of the molecular pathogenesis of infectious disease by a systems biology
approach is especially complicated, in part because pathogens are highly diverse
genetically, multiple phases of the infectious process can be prolonged and
anatomically distinct (e.g. multiple organs), and host immune responses are
multiphasic. (Musser and DeLeo, 2005:1463)
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As previously discussed, the benefits of SB modeling include the identification of
possibly incorrect theories on causality or recognition of dynamic features that cannot
otherwise be observed. While the process may seem unwieldy, Musser and DeLeo assure
researchers that each iterative step of model building and experimentation will provide
new insight. The understanding of gene expression and biomolecular associations can be
increased simultaneously with and through understanding the underlying, mechanistic
biological behavior.
As implied by the title of the article by Musser and DeLeo, a focus on genomewide analysis using massive data sets exists in the SB literature from research institutes
and established laboratories. Made possible by advances in genomics and proteomics
over the last decade, such models are built from the gene up and tested to see which genes
or proteins might have a role in pathogenesis. Several reviews on this type of SB
application to drug discovery have been published in the last few years (Cho an others,
2006; Davidov and others, 2003; Apic and others, 2005). A model of signaling in cancer
cells contained 326 molecular components, referred to as nodes in the model, and 892
chemical relationships between the components. Despite high genetic variability in
cancer cells, the researchers were able to conclude that “clear patterns of oncogenesignaling collaborations emerge recurrently at the network level” by applying the holistic
SB approach to the signal transduction data (Cui and others, 2007:1). An even larger
modeling effort investigated apoptosis through signaling, using multiple stimuli as input
and cytokine production as output for the model, and integrated a massive 7980 signals
with 1440 apoptosis-related responses. By varying two extracellular stimulants, the JNK
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MAPK path was found to have a dynamic “four-dimensional signal-response”
relationship to apoptosis. Three stimulants and nearly 8,000 signals results in 660
dimensions and an unsolvable matrix of coefficients (Janes and others, 2005:1647-1649).
The model was simplified through partial least squares regression and still maintained the
ability to predict 12 apoptosis outputs with multiple stimuli. Combining in vitro lab
experimentation with a “data-driven” systems approach revealed two opposing signal
clusters, one pro-death and one pro-survival, that “capture the dynamic intracellular
signal processing of diverse stimuli, including autocrine-feedback circuits” (Janes and
others, 2005:1653). The previously unknown involvement of autocrine signaling is an
excellent example of how using a holistic systems approach can identify features that
otherwise could not be observed within such a dynamic system. These research efforts,
combined with continuing advancement in genomics and proteomics technologies that
facilitate faster and more accurate data collection, provide a positive outlook for the
future of SB modeling. Unfortunately, at this time they are still limited in application due
to limits in available data and computational methodologies.
However, host-pathogen models can take a “top down” approach that focuses on
a specific signal or cell of interest, addresses a specific problem, and does not demand
intensive data collection (Forst, 2006:221). To advance knowledge signal transduction in
a dynamic network, instead of traditional, linear, non-dynamic statistical correlations,
mechanistic analysis of reaction kinetics by nonlinear ordinary differential equations is
the preferred quantitative modeling method (Cho and Wolkenhauer, 2003:1405; Forst,
2006:222; Smith, 2005:53; You, 2004:172). Top-down, kinetic models are often simple
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and based on a number of assumptions such as the ‘mixed model’ where an enzyme’s
chemical concentration within the cell is considered homogeneous throughout, though in
reality concentrations vary by compartment and by location within a compartment. Such
simplifications do have precedent in successful, widely-accepted toxicological modeling
applications such as the systems dynamics-based physiologically-based pharmacokinetic
(PBPK) modeling, in which the instant mixing and homogeneous chemical concentration
assumptions are made at the tissue scale. To achieve a more accurate dose-response
model, toxicologists should shift away from the paradigm of linear regression of doseresponse data and toward integrating increasing details of signal and biochemical
interaction. To do this, toxicologists must work toward understanding “the underlying
biology prior to evaluating the perturbation of the system following chemical exposure”
(Andersen and others, 2005:328-329). This report attempts to develop the understanding
of biomolecular pathogenesis in inhalational anthrax by implementing a host-pathogen
systems biology model using published, parameterized mathematical models of the
MAPK cascade as the foundation.

Published MAPK Models
As one of the most significant signal path families, the MAPK cascade has been
thoroughly studied in both wet and dry laboratories, in vivo, in vitro, and in silico. A
number of authors have published SB models of MAPK signal transduction with varying
levels of complexity. The models were selected for review and implementation based,
first, on availability of completely parameterized models in the BioModels Database and,
second, on variation presented in the model. BioModels Database is repository of
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mathematical biological models that are intended to be shared through the Internet
(http://www.ebi.ac.uk/biomodels) for the promotion of research. The database is
administered by the European Molecular Biology Laboratory’s European Bioinformatics
Institute (EMBL-EBI) in England. EBI is an academic non-profit member of the EMBL
group, an international organization established in 1974 that now includes five research
centers throughout Europe. Previously, EBI has also been funded in part by the Defense
Advance Research Projects Agency (DARPA) of the U.S. Department of Defense.
As with most modeling of dynamic systems, models should not be too large in
scope so as to encompass components irrelevant to the feature being investigated. Thus,
the selection begins with early, more simple models that identify unique characteristics of
MAPK signaling such as ultrasensitivity, which allows a very quick and strong output
response to a very small stimulus, and oscillatory behavior in the signal output, activated
MAPK. The third model includes the relationship between MAPK enzymes and scaffold
proteins, which bind enzymes in a signal sequence to increase selectivity and decrease
‘cross-talk’ interference between different pathways. Scaffold proteins may exist to
decrease system nonlinearity and thereby “lead to elimination of sustained oscillations”
(Kholodenko, 2000:1587).
Ultrasensitivity Model.
Huang and Ferrell may have been the fist to apply computational modeling to the MAPK
cascade in their paper “Ultrasensitivity in the mitogen-activated protein kinase cascade,”
which was published in the September 1996 Proceedings of the National Academy of
Sciences, now simply known as PNAS. The ultrasensitivity model follows the simplified
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MAPK cascade structure, as shown in Figure 4. The figure includes added annotations -P
and -PP, which represent the singly and doubly phosphorylated MAPKK and MAPK, and
P’ase, an abbreviation for the phosphotases that dephosphorylate both the singly and
doubly phosphorylated forms of MAPKK and MAPK (Huang and Ferrell, 1996:100078).
The kinetic equations in this model explicitly depict the double phosphorylation for
activation of the intermediate and terminal kinases. This is accomplished, for instance,
by including the bound MAPK/MAPKK-PP complex that produces MAPK-P, the
MAPK-P/MAPKK-PP complex that produces the fully active MAPK-PP, and each of the
singly and doubly phosphorylated kinases formation in the bound state with its respective

Figure 4: Schematic of MAPK cascade for ultrasensitivity model
(after Huang and Ferrell, 1996)
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phosphotase, such as the MAPK-PP/MAPKP’ase complex that results in deactivation of
the kinase to MAPK-P. The stoichiometric, chemical equations listed in Huang and
Ferrell (1996) show the detailed association and disassociation reactions for each
enzyme-substrate pairing; the article also includes the time-dependent differential
equations. Huang and Ferrell were able to predict that MAPK would “behave like a
highly cooperative enzyme, even though it was not assumed that any of the enzymes in
the cascade were regulated cooperatively” (Huang and Ferrell, 1996:100078).
Cooperative behavior arises from having multiple binding sites, for which binding of one
affects activity of another, and results in a sigmoidal or S-shaped curve, meaning
behavior does not follow Michaelis-Menten (MM) kinetics (Figure 5). Ultrasensitivity in
cooperative enzymes is measured by the Hill coefficient, nH. The Hill coefficient equals
one for the MM kinetic model and approximately five for the ultrasensitive MAPK
cascade (Ferrell and Machleder, 1998:896). As the term implies, an ultrasensitive signal
is able to react to much smaller changes in the concentration of ligands, the extracellular
molecules that bind with membrane receptors to initiate the signal. For Michaelian
enzymes where nH = 1 “there must be an 81-fold change in ligand” concentration to
increase “from 10%...to 90% maximal enzyme activity,” whereas a non-MM,
“cooperative enzyme with a Hill coefficient of 4 can give the same enzyme activity
change with only a 3-fold variation in ligand concentration” (Goldbeter, 1981:6444).
Huang and Ferrell were subsequently able to validate the model’s prediction of
ultrasensitivity via an in vitro experiment in which the MAPK activity was measured in
Xenopus (frog) oocytes. Like the predicted curve, the empirical sigmoidal curve for
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Figure 5: Ultrasensitivity model-predicted and observed kinase activation levels (in vitro
data from Xenopus oocyte extracts) (modified from Huang and Ferrell, 1996)
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MAPK was found to be much steeper than for an enzyme following normal MichaelisMenten kinetics. The authors predicted and then confirmed the all-or-none, switch-like
behavior known as ultrasensitivity in the MAPK cascade. The kinase activity levels
presented in Figure 5 represent the steady-state activity at varied concentrations of a
cascade stimulant. The time-dependent active MAPK output of the ultrasensitivity model
is shown in Figure 6, in which it can be seen that the steady-state activation is reached in
only 60 seconds. Ultrasensitivity increases with the number of intermediates in the
cascade. This may explain why MAPKs have more steps in the activation chain than
most other signal pathways and why MAPK signaling is “particularly appropriate for
mediating processes like mitogenesis…where a cell switches from one discrete state to
another” (Huang and Ferrell, 1996:100078). Because a macrophage would be activated
during the process of binding and engulfing the spore, LF-induced inhibition of MAPK

Figure 6: Ultrasensitivity model output
(PP_K is MAPK-PP, P_K is MAPK-K, and K is MAPK)

41

activation would likely not affect response sensitivity but would slowly ‘switch off’ the
activation signal as MAPKKs are depleted.
Oscillating Negative Feedback Model.
In “Negative feedback and ultrasensitivity can bring about oscillations in the
mitogen-activated protein kinase cascades” from the 2000 European Journal of
Biochemistry, Kholodenko demonstrated that the MAPK signal would oscillate due to
ultrasensitivity combined with a negative feedback loop in which the terminal MAPK
(E1) inhibits activation of the MAPKKK (E3). Kholodenko refers to Huang and Ferrell
as having a similar cascade structure; the schematic, shown in Figure 7, also uses the

Figure 7: Schematic of MAPK cascade with feedback loop (after Kholodenko, 2000)
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same annotations for the enzyme activation states. However, this schematic denotes
MAPKKK (E3) as MKKK and shows MAPKKK to be activated at the cell membrane by
one phosphorylation from Ras, which is otherwise termed MKKKK by the kinase naming
convention. While adding the negative feedback relationship between activated MAPK
(MAPK-PP) and Ras, Kholodenko excludes the phosphotases that were included in the
kinetic equations by Huang and Ferrell. Because “in vitro enzymatic studies have shown
that dual-specificity kinases (MEK1) follow the Michaelis-Menten mechanism,”
Kholodenko applied MM kinetics in his differential equations (Kholodenko, 2000:1584).
In another deviation from Huang and Ferrell’s model, the kinetic equations are developed
without regard to the transient kinase-to-kinase and kinase-to-phosphotase intermolecular
complexes experienced during kinase activation and deactivation, respectively. Robinson
and others developed and implemented a first attempt to model the LF-MAPKK
interaction using Kholodenko’s model, which was selected for being the most simple
model available (Robinson and others, 2007). That initial anthrax host-pathogen model,
which was presented in the poster session of the 5th Annual American Society for
Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting in 2007,
provided the precedent for this research effort.
Kholodenko’s significant contribution is the negative feedback loop in which the
active MAPK inhibits Ras activation through phosphorylation. As a result, an increasing
concentration of active MAPK results in decreased production of more active MAPK. As
MAPK then decreases in concentration, stimulation at the cell membrane overcomes the
inhibition; this causes MAPK-PP concentrations to begin to increase again. Eventually,
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the concentration again affects inhibition, and the oscillatory cycle repeats as depicted in
Figure 8. The oscillation of MAPK-PP levels was a model-derived prediction by
Kholokenko, and that prediction has been reported as being observed in the laboratory by
other researchers (Sauro and Kholodenko, 2004:26). The removal of the stimulus that
generates the switch-like response would result in damped oscillations, until steady-state
is reached by the system output. Of course, due to phosphotase activity on the active
MAPKs, LF would continue to inhibit active MAPK such that, unlike a cessation of
stimulation, it falls below baseline levels required for cell function regulation.
MAPK Model with Scaffold Proteins.
In the same year as the publication of the oscillatory model in the Europe,
Levchenko, Bruck and Sternberg published a MAPK model in the United States under the

Figure 8: Feedback model output showing MAPK-PP oscillations
(after Kholodenko, 2000)
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title “Scaffold proteins may biphasically affect the levels of mitogen-activated protein
kinase signaling and reduce its threshold properties” in PNAS. Scaffold proteins “serve
as organizing centers for signal transduction because they can bind several members of a
signaling cascade to form a multimolecular complex” (Levchenko and others,
2000:5818). The model was built to demonstrate that “formation of scaffold–kinase
complexes can be used effectively to regulate the specificity, efficiency, and amplitude of
signal propagation” (Levchenko and others, 2000:5818). The bound complexes of
scaffold proteins and kinases are in the model equations as unique chemical species, but
in a non-transient form, unlike the kinase-phosphotase complexes used by Huang and
Ferrell. Simplified diagrams of the postulated scaffold-kinase complexes are shown in
Figure 9; only the transitions for the unbound scaffold are shown (solid arrows) for
clarity. The scaffold-facilitated reactions are denoted on the bottom of Figure 9 by the
dashed arrows. Some MAPKKs (the E2 level) have even been found to act in both the
role of a kinase and a scaffold protein. Due to the high number of nodes (86 kinases,
kinase-kinase complexes, kinase-phosphotase complexes, and scaffold complexes, with
three states of kinase phosphorylation) and reactions (300), a schematic of the scaffold
model is too large and intricate to be presented here.
The scaffold model includes the kinase-deactivating phosphotase components like
Huang and Ferrell, but referencing early works on biochemical ultrasensitivity and MM
kinetics (Goldbeter and Koshland, 1981, 1984), Levchenko et al instead apply M-M
kinetics like Kholodenko. Modeling MAPK complexes with a generic scaffold protein
shows that scaffold proteins “can substantially increase the signaling output”; but
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Figure 9: Examples of kinase-scaffold protein complexes and transitions
(‘K’ is MAPK, ‘KK’ is MAPKK, and ‘P’ is a phosphate group on a kinase)
(modified from Levchenko and others, 2000)

alternatively “if the scaffold concentration is greater than optimal, a significant decrease
in signaling can occur” (Levchenko and others, 2000:5818). Figure 10 reflects the output
of MAPK-PP concentration over time using the scaffold protein model as downloaded
from BioModels Database. Figure 11 demonstrates this optimization concept through a
graph of the model output with different concentrations of the two-kinase scaffold
complex, where increasing two-member concentration increases kinase activity. At some
point a threshold is crossed and the 1 micromolar (μM) concentration results in a
significant drop in MAPK-PP concentration that is lower than activity without scaffold
proteins. This may present a reason why analysis of some kinases in scaffold complexes
within the cytoplasm appear to be inhibited, perhaps because the scaffold limits kinase
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Figure 10: Scaffold protein model output for active MAPK levels

Figure 11: MAPK activation as a function of fully-bound scaffold concentration
(modified from Levchenko and others, 2000)
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enzyme mobility in the cytoplasm, compared to tests with purified, unbound enzymes. If
the concentration of the scaffold protein in the cytoplasm is over the optimal level, then
the signal response is reduced below its potential; a reduction in the expression of the
scaffold protein could increase the output beyond that possible in tests with unbound
enzymes.

Summary
Macrophages eagerly ingest anthrax spores but, upon spore germination, are
disabled by the LF inhibition of MAPK signal transduction, resulting in accelerated
programmed cell death and a failure to activate the full immune response. Though
variation exists between MAPK activations and subsequent effects, macrophage
apoptosis depends on multiple pathways, and LF is known to inhibit nearly all MAPK
pathways by cleaving MAPKKs, the E2 intermediates. Combining published systems
biology models of the MAPK cascade with laboratory data for cell viability of
macrophages cultured with LT-producing strain of anthrax, a model of the host-pathogen
dynamic system is feasible.
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III. Methodology

Overview
All models have been developed from published, fully-parameterized MAPK
cascade models obtained through BioModels Database (http://www.ebi.ac.uk/biomodels),
which facilitates systems biology research through the sponsorship of EMBL-EBI. The
following procedure, mostly derived from the procedure for a first attempt to model the
LF-MAPK interaction by Robinson and others, was used to modify three models to
include LF-induced cleavage of MAPKKs and to translate software-specific code for the
parameters and equations (Robinson and others, 2007). By varying the kinetic reaction
rate constants defining the cleavage of MAPKKs by LF, the model output, which is the
MAPK-PP concentration or MAPK activation level, was adjusted to fit empirical
macrophage cell viability data for two LT-sensitive murine macrophage cell lines cocultured with a LT-producing strain of B anthracis.

Model Development
The models were downloaded from BioModels in Standard Biological Mark-up
Language (SBML), an XML-based computer language developed explicitly for
computational modeling of biological processes. The SBML code was imported into
JDesigner (version 2.0.41), a free, open-source program that was developed for systems
biology modeling with the support of DARPA and the U.S. Department of Energy.
Within JDesigner, each model was modified to add the chemical reactions accounting for
the cleavage of MAPKKs (the E2 intermediate from Figure 1). The catalytic reaction was
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assumed to possess first-order linear kinetics; the kinetic constants for the reactions were
initially approximated using the values from the initial effort by Robinson and others.
The code of each model was then exported from JDesigner and modified, using the
procedure described in Appendix B, to allow the code to be imported into Berkeley
Madonna (version 8.3.11). Berkeley Madonna is a general purpose differential equation
solver developed by faculty at the University of California at Berkeley through the
sponsorship of the National Science Foundation and National Institutes of Health.
Thought not explicitly a systems biology modeling tool, Berkeley Madonna was selected
for model implementation because it is a significantly faster ordinary differential equation
(ODE) solver and because it allows variables to be more easily manipulated than
JDesigner. Berkeley Madonna is also the modeling program in use by the research
sponsor, AFRL/RHPB. The edited code that was run in Berkeley Madonna for each
model is provided in Appendix C. Though parameter values were varied in determining
the effective reaction rate constants, the code reflects only one value per parameter.
Chemical Reaction Kinetics.
All models were used in their published form, as downloaded from BioModels
Database. One exception occurred in the MM kinetic equations established by
Kholodenko for the oscillating negative feed back model with regard to strength of the
negative feedback. The power in the first reaction rate equation in the oscillating model’s
code, provided in Appendix C, determines the level of negative feedback, where n = 2 is
approximately equivalent to cooperative inhibition (Kholodenko, 2000:1586). (The
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variable is ‘n’ in the published equations and is coded in the rate equation as the kinetic
parameter ‘J0_n.’) Both presentations of negative feedback power were investigated.
As discussed in Chapter II, the literature is clear in statements that LF cleaves all
MAPKK isoforms, with the one exception of MEK5. However, nothing could be found
in the literature regarding the possibility of LF reacting differentially with the three
phosphorylation states of the E2 intermediate. The phosphorylations occur at two amino
acids among hundreds in the polypeptide chain, whereas LF recognizes a specific site
adjacent to the N-terminus of the protein (Bardwell and others, 2004:576). Each
subsequent phosphorylation may affect the affinity and reactivity of LF with its
substrates, via changes in diffusive or electrophoretic mobility of MAPKKs within the
cytoplasm, but the available literature contains no analysis or even suppositions regarding
proteolysis being dependent on phosphorylation or activation state.
When a macrophage is challenged, the macrophage is activated, signaling
initiates, and MAPKs are rapidly phosphorylated. In the case of the ultrasensitivity
model, biphosphorylation becomes the predominant state for MAPKKs; logically, LF
would have to cleave the biphosphorylated, active MAPK in order to accomplish
cytolysis via pathway inhibition. In the negative feedback model output seen in Figure 8,
the concentration of biphosphorylated MAPK, MAPK-PP, varies over a significant range
of concentration (approximately 40 to 300 µM). As a consequence of the negative
inhibition exerted by MAPK-PP on activation of the initial, E1 level of the cascade, the
concentrations of the three phosphorylation states of MAPKK also oscillate. Within the
third model, in which MAPKKs are bound to scaffold proteins, the mobility as a function
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of the number of phosphorylations is presumably insignificant compared to mobility
restrictions as a result of the scaffolds. It is therefore assumed herein that LF reactivity is
inclusive of all unphosphorylated, monophosphorylated and biphosphorylated MAPKK
isoforms. Because the rapid switch-like nature of MAPK activation and deactivation
shows that all forms of kinases are readily accessed within the cytoplasm, and in the
absence of data indicating otherwise, kinetic values for the three phosphorylation states of
MAPKK were assumed to be equal. Finally, one study has shown that MAPKKs
continue to interact with and be phosphorylated by MAPKKKs at the start of the cascade.
Active MAPKKs may also behave normally in other cellular interactions outside the
MAPK cascade, but are only unable to recognize and bind with MAPKs due to the loss of
the amino-terminus, which is part of the docking site (Paccani and others, 2005:329). As
suggested in the literature review, studies have shown reduced intrinsic kinase activity in
addition to significant loss of interaction between MAPKK and its substrates as a result
of proteolysis (Chopra and others, 2003:9402). The models thus assume that all
incomplete forms of MAPKK, regardless of activation state, are chemically no longer
functionally MAPKKs due to the inability to activate MAPKs.
All models were treated similarly with regard to implementing the first-order
reaction kinetics for catalytic cleavage of MAPKKs by anthrax lethal factor. Being
produced by a bacterium in a phagosome within the macrophage, the chemical
concentration of lethal factor was assumed to be sufficient for sustained catalytic reaction
(Park and others, 2002:2049), therefore LF was not included in the models as a chemical
species. The equations for the three models all followed the same structure for a time-
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dependent ordinary differential equation, which is represented here using the traditional
brackets around chemical species to denote concentration and using k as the variable for
the reaction rate constant (Engel, 1977:15):
d[Cleaved MAPKKs]/dt = [Cleaved MAPKK] + [Cleaved MAPKK-P]
+ [Cleaved MAPK-PP]

(1)

where,
[Cleaved MAPKK] = kKK [MAPKK]

(2)

[Cleaved MAPKK-P] = kKKP [MAPKK-P]

(3)

[Cleaved MAPK-PP] = kKKPP [MAPKK-PP]

(4)

Again, the three rate constants (k) for LF cleavage are assumed equal. Each model
applies different initial concentrations for the three MAPKK phosphorylation states based
on the sources referenced in each respective publication. A model node was added in
JDesigner to represent the accumulated products of the three cleavage reactions, and the
-1

initial parameter value was assigned at the estimated 2.5e-4 s established in previous
model work (Robinson and others, 2007). Following basic functional testing to ensure
operability of the model in JDesigner, models were translated for import into and
parameterization in Berkeley Madonna.
In Berkeley Madonna, each model was manipulated and evaluated using
procedures described in model-specific detail within the results. The output for all
models was the active terminal MAPK (MAPK-PP), for which concentration was plotted
against time. The behavior of the output was compared to data on the viability of two
standard, LT-sensitive murine macrophage cell lines, RAW264.7 and J774.1, which were
cultured for at least 15 hours with Bacillus anthracis-Vollum 1B (V1B), a virulent strain
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of BA that produces LT and a “capsule that inhibits phagocytosis of vegetative BA”
(Gutting and others, 2005). The graphs in Figure 12 represent two separate experiments
to assess cell death in two macrophage cell lines cultured with and without Bacillus
anthracis-Vollum 1B. While the two cell types shown are differentially susceptible to
LT, the overall behavioral trend is similar, especially when considering error. Fitting to
the data for the two cell lines, each model was parameterized for first-order reaction
constants for lethal factor’s catalytic reaction with MAPKKs.
Ultrasensitivity Model.
The ultrasensitivity model includes MAPKKs in a bound complex form
(“BIOMD0000000009- Huang1996_MAPK_ultrasens,” 2007). For instance, MAPKKK

Figure 12: Macrophage viability when cultured alone or with V1B
(modified from Gutting and others, 2005)
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(E3) interfaces with MAPKK (E2) to activate it; and this interaction is explicitly
represented as a transient multi-molecular species (node) within the model. Cleavage of
LF substrates while bound to other macromolecules presented a problem: without a more
complex kinetic model, a first-order reaction with MAPKK while bound would have also
subtracted from the pool of the other complex member. These transient species exist only
during the recognition and phosphorylation of the kinase substrate or the
dephosphorylation of the phosphotase substrate. The available concentration and time for
LF proteolysis of a MAPKK while in such a kinase-kinase or kinase-phosphotase
complex are assumed to be minimal; therefore it was assumed that LF did not actively
cleave the bound MAPKKs. This assumption was validated after tuning the LF/MAPKK
reaction kinetics to fit the J774A.1 cell line data. Only doubly phosphorylated MAPKK
exists in complexes at appreciable concentrations: the MAPKK-PP/MAPK complex
peaks under 0.05 µM, and the MAPKK-PP/MAPK-P complex peaks under 0.09 µM
(Figure 13). For comparison, unbound MAPKK begins at 1.2 µM and is quickly
activated, resulting in slightly over 0.8 µM MAPK-PP. Thus, LF interaction with the
transient MAPKK (E2) complexes was ignored.
Oscillating Negative Feedback Model
Minor modifications have been made for application of the negative feedback
model and for comparison to the macrophage viability data. The oscillation model
downloaded from BioModels Database starts with an initial (t = 0) MAPK-PP
concentration of 10 μM, so the absence of phosphotases in the model would result in a
steady-state 10 μM concentration after damping of the oscillation via depletion of

55

Figure 13: Ultrasensitivity model’s low bound MAPKK complex concentrations

MAPKKs (“BIOMD0000000010 – Kholodenko2000_MAPK_feedback,” 2007). This
may not be optimal for simulating inducement of apoptosis if the baseline value is
sufficient to sustain inhibited functions to be modeled later. The model output published
by Kholodenko, shown Figure 8, shows an initial MAPK-PP concentration of zero;
another published figure (not shown) related to evaluation of the effect of cooperative
inhibition does show an initial concentration of 10 μM for MAPK-PP. To permit full
deactivation of the active MAPK pool by phosphotases, the initial MAPK-PP
concentration was changed to zero (coded as “init MAPK-PP = 0” as shown in Appendix
C). Second, the cell viability data from Figure 12 have been time-shifted by 5 hours to
take into account the time required for germination and gene expression prior to the
production of LT. The first data point at the five-hour point has a cell viability of 100%
and, for the purposes of the model, is reset to t = 0 because LT-induced inhibition of
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MAPKs begins immediately. Finally, as stated above, the MM kinetic parameter for
power of the negative feedback loop, n, was varied as shown in publication.
The presence of oscillations had to be accounted for in the process so that the
average MAPK-PP concentration could be fit to the data. The model was run as a MAPK
signal model without the presence of LF so that the natural oscillations could be
observed. Because the active MAPK effectively ‘spends more time’ at the oscillation
peaks than at the minimums, the average is weighted toward the peaks. The numerical
output was exported from Berkeley Madonna; the peak, minimum, and average active
MAPK concentrations were determined using Microsoft Excel 2003. The average
MAPK without LF-induced MAPKK cleavage was graphed as equivalent to the 100%
macrophage viability. As seen in the results, respective fractions of the average were
applied as appropriate for each cell line and negative feedback loop strength combination.
MAPK Model with Scaffold Proteins
Like the ultrasensitivity model, the scaffold facilitated model involves
biomolecular complexes between kinases, phosphotases, and scaffold proteins
(“BIOMD0000000014 – Levchenko2000_MAPK_scaffold,” 2007). The scaffold protein
complexes, however, are not assumed to be transient and limited in concentration relative
to unbound targets of the toxin. Following the same argument for the ultrasensitivity
model, where reaction with bound kinases would also deplete the scaffold proteins, the
interaction of LF with the bound MAPKKs was ignored. This presents a significant
limitation in applying this model to LF cleavage of MAPKKKs due to the model focusing
on the promotion of kinase activation via these sustained complexes. Because the
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catalysis cannot be applied to a significant portion of the MAPKK population in the
model, the kinetic constants applied to the unbound forms will be overestimated to
compensate.
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IV. Analysis and Results

Chapter Overview
Each MAPK cascade model was modified to include LF proteolysis of MAPKKs
via a first-order reaction. The model output, active MAPK, was plotted, and the kinetic
reaction rate constants for the cleavage of MAPKKs was parameterized to fit the in vitro
data for the RAW264.7 and J774A.1 macrophage cell lines (Figure 12). The models
designed around the ultrasensitivity and negative feedback characteristics were able to be
manipulated to fit the cell viability data, and for the latter the strength of the feedback
loop was evaluated in relation to the laboratory results. Unfortunately, the scaffold
protein model proved to be a poor model for investigating LF-induced inhibition of the
MAPK cascade. The model was only unable to provide a fit for the J774A.1 viability
data and resulted in a high cleavage rate estimate for the RAW macrophage cell data;
both are likely due to the limitations of the model imposed by the binding of MAPKKs to
scaffold proteins.

Results of Simulation Scenarios
Ultrasensitivity Model
The ultrasensitivity model results in an S-curve of the MAPK activation and
quickly approaches steady-state (Figure 6). Though still present, the switch-like response
to the bacterial stimulus is not perceptible in the output due to the time scale of the
anthrax incubation (15 hr). At first glance, the ‘reverse’ S-curve showing inhibition of
MAPK activation appears to match the behavior of the J774A.1 macrophage viability plot
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better than the inverse shape of the RAW264.7 viability plot. However, it should be
noted that the RAW viability at 10 hr in Figure 12 shows a lower bar of the range or error
at approximately zero; this indicates that the actual behavior of the RAW cell line when
incubated with LT-producing BA may be closer to that of J774A.1 cells than implied by
the simple linear data point connectors in Figure 12. Additionally, the error bars plotted
represent the standard error of the mean (SEM) instead of standard deviation (SD) with a
confidence interval. According to a report on misuse of the SEM in biomedical research:
Authors often use the [SEM] to describe the variability of their sample… As the
SEM is always smaller than the SD, the unsuspecting reader may think that the
variability within the sample is much smaller than it really is… The SD tells us
the distribution of individual data points around the mean, and the SEM informs
us how precise our estimate of the mean is. It is therefore inappropriate and
incorrect to present data only as the mean (SEM)… The use of the SEM should be
limited to inferential statistics where the author explicitly wants to inform the
reader about the precision of the study. (Nagele, 2001:514)
Given that the SEM range is very near to zero and that an SD-derived confidence interval
would likely result in a larger range, a viability of zero is therefore assumed to be within
the confidence interval. With parameters set according to the code in Appendix C and
with all three reaction constants for LF cleavage assumed equal, parameterizing to fit the
-1

in vitro data for RAW264.7 results in a reaction rate of 2.95e-4 s (Figure 14). The curve
has 25% activation at 2.5 hours (9,000 s), per the in vitro analysis, and near-zero
activation at 5 hours (18,000 s), which is within the range of error.
The kinetic parameters for LF reactivity in the J774A.1 cell line were more easily
obtained. The range of error for the 5-hour data point (10-hour point in Figure 12, minus
the 5-hour shift), using SEM, is approximately 40% to 60%. This corresponds to first-1

order constants of 1.2e-4 s to match 50% viability at 5 hr (18,000 s), with a range of
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Figure 14: Ultrasensitivity model parameterized to fit RAW264.7 in vitro data (dots)

-1

-1

1.1e-4 s for 60% viability up to 1.3e-4 s , for 40% viability. Corresponding to the in
vitro data, the fit for 40% viability at 5 hours (18,000 s) also corresponds to a near-zero,
1% viability at 10 hours (36,000 s) (Figure 15). The data for both cell lines is provided in
Table 2 following discussion of the results for the other models.
Oscillating Negative Feedback Model
The negative feedback model presents a challenge in that the average of the
oscillations must be fit to the empirical cell line data. Figures 16 and 18 illustrate the
results of fitting the data using the non-competitive inhibition model where n=1, for
which results in an oscillation peak at about 287 µM and a minimum around 36 µM,
giving an initial amplitude of 125 and, due to the oscillation spending more time at the
peaks than the valleys, an average of about 184 µM prior to MAPK inhibition. The
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Figure 15: Ultrasensitivity model parameterized to fit J774A.1 in vitro data (dots)

-1

rate constant for the RAW264.7 data (Figure 16) with n=1 is 2.9 e-4 s , and the rate is
-1

1.2 e-4 s for J774A.1 macrophages (Figure 17). The stronger negative inhibition (n = 2)
is applied in Figures 17 and 19 to give an oscillation peak near 288 µM and a minimum
of about 9 µM, for an amplitude of approximately 140 and an average of 175 µM. For
-1

n=2, the rate constant for the RAW264.7 viability data (Figure 18) is 2.3 e-4 s , and the
-1

rate is 9.5 e-5 s for J774A.1 macrophages (Figure 19). At a glance, Figures 17 and 19
appear to demonstrate a better match to the data behavior due to having full loss of
MAPK-PP (0% cell viability) at a later time point. One might expect the stronger
inhibition of the cascade’s initial activation step via the negative feedback loop to result
in a more rapid loss of active MAPKs, but both outputs for increased negative feedback
show more oscillations at 5 hours (18,000 s) and a later x-axis intercept. Kholodenko
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Figure 16: Negative feedback model (n=1) fit to RAW264.7 data (dots)

Figure 17: Negative feedback model (n=2) fit to RAW264.7 data (dots)
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Figure 18: Negative feedback model (n=1) fit to J774A.1 data (dots)

Figure 19: Negative feedback model (n = 2) fit to J774A.1 data (dots)
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notes that an increase in kinase concentrations or in the MM kinetic parameter KM could
cause the oscillations to transition to a stable state, but increased negative feedback
allowed oscillations to reemerge (Kholodenko, 2000:1586). This suggests that SOS
(effectively an MKKKK) may be inhibited via double phosphorylation from MAPK
(Kholodenko, 2000:1586), but the fit appears better for the confidence in the models,
having been qualitatively fit to the data to determine the parameters, do not allow any
conclusion regarding whether MAPK cooperatively inhibits SOS/MKKKK through
double phosphorylation.
MAPK Model with Scaffold Proteins
The scaffold protein model was not well suited for the modeling of LF cleavage of
MAPKs resulting in macrophage cell death. The RAW264.7 cells could be adequately fit
-1

with a high reaction rate constant of 5.9e-4 s , which is twice that of the other models for
this cell type (Figure 20). Unfortunately, the behavior of the J774A.1 macrophages could
not be reflected in the model. Dropping the rate constant to a value of 1.0 e-4 did
increase the MAPK activation sufficiently to reach the lower SEM limit of 40% viability
at five hours, but the 10-hour activation was elevated well above zero (Figure 21).
Assuming that the rate constants are equal for all three activation states of unbound
MAPKKs, no single number can be found to fit the in vitro MAPK activity levels
observed in the J774A.1 cell line. As discussed previously, this is likely due to the high
proportion of MAPKK bound in complexes with scaffold proteins.
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Figure 20: Scaffold protein model fit to RAW264.7 data (dots)

Figure 21: Scaffold protein model showing poor fit to J774A.1 data (dots)
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Summary
The ultrasensitivity and negative feedback models were able to be parameterized
to fit the in vitro data for the co-culturing of macrophage cell lines RAW264.7 and
J774A.1 with Bacillus anthracis. The model in which MAPKKs are bound to scaffold
proteins was unable to fit the data for J774A.1, possibly due to the exclusion of the bound
substrates of LF. No data whatsoever could be found in the literature for kinetic reaction
rate constants for the cleaving of kinases by LF. The reaction rate constants for the
cleavage of all isoforms of bi-, mono- and unphosphorylated MAPKKs by the protease
LF were thus estimated for the three published models. The estimated rate constants,
which are summarized in Table 2, show a reasonably consistent performance by the
models in estimating a LF-MAPKK reaction rate parameter for each macrophage type.
Additionally, ratio of the rate constants is approximately the same, around 2.3 to 2.4, for
the three simulations fit to both cell lines. While the two versions of negative feedback
loop intensity resulted in different estimates for the kinetic constant, the relative
sensitivity of the two macrophage cell lines was about the same for both n=1 and n=2
feedback mechanisms. This consistency demonstrates the robustness of the models.

Table 2: Kinetic constants for LF cleavage of MAPKKs
Macrophage
Ultrasensitivity
Cell Line
RAW264.7

2.95e-4 s

J774A.1

1.3e-4 s

Ratio

2.3

-1

-1

Negative
Feedback
(n=1)
2.9e-4 s
1.2e-4 s
2.4
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-1
-1

Negative
Feedback
(n=2)
2.3e-4 s
9.5e-5 s
2.4

-1
-1

Scaffold
Proteins
5.9e-4 s
no fit
n/a

-1

V. Discussion and Conclusions

Discussion
The mitogen-activated protein kinase (MAPK) pathways mediate critical
intracellular communication to enable regulatory functions such as gene expression,
survival and apoptosis. The broad capability of Bacillus anthracis to suppress cellular
and system-wide immune response hinges first on the pathogen’s ability to use the
macrophage as a Trojan horse in its attack on the immune system. While decades of
laboratory analysis have advanced the general understanding of the pathogenesis of
inhalational anthrax, the role of the toxin components, and the cytotoxic mechanisms
resulting in apoptosis are still unclear. Advances in genomic and proteomic technologies
led to the mapping of the human genome, and in the post-genome era a plethora of data
can be generated on cellular components and their functions. With computer technology
and the development of computational methods, these reserves of biochemical data have
made mathematical modeling of complete microorganisms a possibility.
Such advanced models must be built in phases. Some systems modelers apply the
top-down approach of establishing a far-reaching model and then applying simplifications
until the behavior of concern can be seen in the system, enabling them to see what
biomolecular components play a role in the behavior. As in the case of the MAPK
models, some biologists conduct research using the bottom-up approach of modeling a
single signal transduction pathway to study it for unexpected behaviors, form testable
hypotheses, and guide laboratory analysis that will facilitate additional improvements to
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the modeling process. Within this research, no unique microbiological study was
conducted for comparison; these models were developed with previously published in
vitro viability data for RAW264.7 macrophages and J774A.1 macrophages that were
incubated after phagocytosis of LF-producing spores. Models are often based on data
collected for a specific MAPK isoform, but stimulants are not generally isoform-specific
and inhibitors can have unpredicted effects that influence the results. The various
MAPKK isoforms are treated here as a single chemical species because LF acts
destructively on nearly all MAPKKs, because the redundancies and cross-over
interactions between pathways are not well defined, and because no MAPK models exist
that would support a more detailed, isoform-specific model.
The three MAPK models investigated here exhibit specific characteristics
(ultrasensitivity, negative feedback and scaffold proteins) and were developed by their
respective authors for the purpose of studying these respective aspects of the MAPK
pathway. By adding the depletion of MAPKKs by anthrax lethal factor (LF), the known
inhibition of the MAPK signal output is be observed, and the reaction rate constant for
MAPKK cleavage has been approximated. For the scaffold protein model, only one cell
line’s viability could be matched, and the resultant approximation of the rate constant
from that parameterization is twice that estimated by the other two models. Presumably
due to the dominance of bound substrates that are unavailable for cleavage, the model
does not adequately capture the behavior of the system. However, the ultrasensitivity and
negative feedback models both exhibited similar behavior and ability to match both cell
viability data sets. The application of a stronger negative feedback mechanism in the
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oscillating models results in a lower minimum active MAPK concentration but does not
alter the periodicity of the oscillations. Without more data on cell viability, either more
information regarding the error or more time points over the duration of the experiment,
both formulations for negative feedback must be considered equally able to reflect system
behavior. The negative feedback model does present a challenge because the average of
the oscillations must be used to fit the data and because change of curve shape is more
difficult to define. In general, the two simple cascade models are equally capable of
fitting the data. The application of the model would likely influence selection. A study
of the kinetics inside a cell, such as might be used to study the effect of changes in the
expression of immunoregulatory genes, may apply the negative feedback model for its
more accurate reflection of intracellular interactions. Comparatively, a study using
cultures or approximating the effects of cytokines in tissue would observe a multitude of
cells signaling and expressing cytokines simultaneously, and may apply the
ultrasensitivity model for a better approximation of the overall chemical concentration
contributing to the effects observed in the system.
Excluding the scaffold model, the approximations for the kinetic constants are
reasonably consistent. For the RAW264.7 cell line, the LF cleavage reaction occurred at
-1

a rate of approximately 3.0e-4 s using both the ultrasensitivity and the n=1 negative
-1

-1

feedback model. These two models resulted in rates of 1.2e-4 s and 1.3e-4 s ,
respectively, for the J774A.1 macrophages. (This close agreement between the two
models hints that the action by which MAPK inhibits cascade activation may be a single
phosphorylation and not equivalent to cooperative inhibition.) The stronger negative
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-1

feedback when n=2 resulted in slightly lower estimates of the rate constants (2.4e-4 s for
-1

RAW264.7, and 9.7e-5 s for J774A.1), which is to be expected since stronger selfregulated inhibition by the pathway output reduces the amount of inhibition work that
must be done by LF. Specific concentrations used by the authors in the different models
did result in different output (MAPK-PP concentration) seen in the results section, but the
different parameter values did not appear to significantly affect the estimates of LF
reactivity, an aspect of system behavior. While the increased internal negative feedback
did not significantly change the oscillations, the increased internal negative feedback does
appear to affect the ability of the system to resist interference.
In the third model, the MAPKKs bound with scaffold proteins are a significant
pool of the total available MAPKK population. This effectively limits the elimination of
MAPPKs by LF, so inhibition in RAW cells could only be achieved by applying a rate
-1

constant of 5.9e-4 s , which is twice that estimated in the other two models. The
inability of the scaffold model to fit the data for the second cell line indicates that the
application of the model does not accurately reflect system behavior and makes the rate
constant estimate for the first cell line suspect. The complexity of the scaffold model was
much greater than that of the other two; the level of detail in the kinetics added should
likely be on par with the kinetics of the base model to obtain reliable results. Model
accuracy depends on whether a model correctly defines the underlying biochemical
relationships, such as the identification of feedback loops, because it is the structure of
the model that determines system behavior. The inclusion of structural aspects
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(biochemical species and interactions) that are not relevant to the investigative question
should be omitted, so as to not overshadow or overpower the behavior being analyzed.
The estimated rate constants for the reaction between LF and MAPKK also
exhibit an interesting trend: for the ultrasensitivity and negative feedback models,
respectively, the reaction rate is estimated as being 2.3 and 2.4 times higher within the
RAW264.7 macrophages than within the J774A.1 macrophages. The use of stronger
feedback loop did have a minor effect on the estimated rate constant; but both of the
inhibition parameter values (n=1 and n=2) provided a ratio of 2.4 between the two cell
lines’ reaction rates. The model’s consistent estimation of a kinetic parameter’s value
under differing inhibitory strengths indicates an ability of this systems biology model to
predict approximate relative susceptibility of a cell type to anthrax infection or toxin
effects. The ultrasensitivity-based host-pathogen model can be used to guide research for
inhalational anthrax in cultures of human alveolar macrophages, the cell type of interest
in development of a human dose-response model. The ability to predict relative
susceptibility between cell types should also apply to cells from different species.
Knowing the relative susceptibility of the cells that facilitate the development of disease,
the models would then also be able to increase confidence in the extrapolation of in vivo
animal data regarding pathogenesis as well as therapeutic agents and the manipulation of
gene expression as methods to combat infection.

Significance of Research
This research presents what is believed to be the first host-pathogen systems
biology model of anthrax infection. Though a great deal of work must first be done to
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achieve it, the goal from a toxicologist’s or emergency responder’s perspective is a
human dose-response model that enables accurate health risk assessments following an
intentional aerosol release of anthrax spores. Models of transport of the bacteria to the
lymph nodes by macrophages and of systemic infection must first be accomplished. For
this model, the approximated kinetic parameters may provide guidance in future research
to quantify the rate constants for these cell lines and possibly others. As just discussed,
the ability of the models to provide consistent approximations of relative susceptibility to
infection may promote the use of systems models to increase confidence in extrapolation
between cell types, tissue sources, or species. This model can serve as the starting point
for expanding the model to include changes in cytokine expression due to MAPK
inhibition, to add edema factor and protective antigen interactions, or to integrate the cell
surface receptors that are bound by protective antigen and permit the entry of the toxins.
LF can be added as a chemical species to develop concentration-dependent dose-response
models for evaluation of cellular effects other than apoptosis or necrosis or for evaluation
of therapeutic agents, such as those that would bind LF, inhibit MAPKK proteolysis, or
up- and down-regulate genes to counteract the effects of MAPK inhibition.

Recommendations for Future Research
More cell viability data is needed to validate the models’ predictive power.
Biological variability is compounded by analysis being conducted in vitro, outside of the
actual environment of infection and in the absence of other stimuli and factors that exist
in vivo. The human alveolar macrophage would be the best model for co-culture of
Bacillus anthracis. For any cell type tested, more time point analyses are needed to
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present a better picture of behavior that can be used to tune and validate models.
Because many other stimuli exist and can activate or suppress MAPK signal pathways,
cell viability data for macrophages exposed to purified LF or LT would also be beneficial
so that the kinetic parameter estimates could be more confidently attributed to the LFMAPKK interactions rather than signaling effects due to other stimuli or inhibitors.
Within cell signaling work, the complete interactions of the MAPK cascade, such
as the negative feedback loop, must be included to correctly predict system behavior.
Research should continue to increase understanding of the intra-cascade interactions and
identify other possible positive or negative feedback loops. Though nearly all MAPKKs
are cleaved by LF, not all MAPKKs have been implicated in immune response regulation.
An isoform-specific MAPK model may better be able to predict cell death and other
effects, such as cytokine suppression. This effort may be worth a second attempt if such a
detailed model becomes available. Also regarding specificity of LF interactions, this
paper questioned the possibility of LF reacting differentially with the bi-, mono-, and
unphosphorylated forms of MAPKK. Binding can change the shape of a protein, and
phosphorylation changes the mass and thereby possibly diffusion, therefore this
possibility may require further investigation. Also, a more complete kinetic model that
includes the LF interactions with scaffold-bound MAPKKs is needed to more accurately
represent the true intracellular signaling mechanisms.

Summary
Host-pathogen systems biology provides a holistic approach to understanding the
dynamic response of a cell to pathogenic challenge and, in the case of B anthracis, to
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toxins that make infection possible by manipulating the intracellular signal network. This
work has expanded on the first model by Robinson et al by including all of the
phosphorylated states of MAPKK as substrates of the proteinase, LF. While attempting
to find one ‘best’ model to reflect the behavior of macrophages, two host-pathogen
models have been developed, parameterized and found acceptable for investigating the
inhibition of MAPK signaling by anthrax LF. The ultrasensitivity and negative feedback
models can now both be used in additional modeling efforts such as adding edema factor
interactions, TNF-α inhibition, or LF concentration-dependence to gain a more complete
and accurate approximation of the biological system’s behavior. Both of these models
can be used concomitantly with empirical data to reflect macrophage system behavior and
estimate unknown parameters with seeming consistency, even between cell types. The
two models can now also be used for aiding in vitro experimental design, such as for the
determination of a range of enzyme concentrations under which a given behavior can be
observed. This work confirms that parameter estimates can generally be made
irrespective of the specific chemical species and parameter values applied in the starting
model. In conclusion, both parameterized models for inhibition of the MAPK cascade by
lethal factor can be used as a foundation for advancing toward a more complete anthraxmacrophage host-pathogen systems biology model.
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Appendix A: Glossary of Terms, Acronyms and Abbreviations

Definitions contained in this appendix are blended from two medical dictionaries,
The American Heritage Stedman’s Medical Dictionary (2nd edition) and Dorland's
Illustrated Medical Dictionary, which is provided on-line through Merck & Co, unless
otherwise specifically cited. Other references included and specifically cited, where
applicable, include: Molecular Cell Biology by Lodish and others; Immunobiology (5th
edition) by Janeway and others; The Cell: A Molecular Approach (2nd edition) by
Cooper; and Casarett & Doull’s Essentials of Toxicology by Klaassen and Watkins. A
list of acronyms and abbreviations are also provided after the definitions.
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Term/Acronym

Definition

adaptive (acquired)
immunity

Immunity obtained from the specialized lymphocytes and resultant
antibodies which are activated by innate immune cells in response
to an antigen; or obtained from the transmission of antibodies, as
from mother to fetus through the placenta; able to protect from
and provide increased immune response to future infection by the
specific antigen (Klaassen and Watkins, 2003)

alveolar
macrophage (AM)

Rounded, mononuclear, vigorously phagocytic macrophage in
alveoli that ingests inhaled particulate matter

andenylate cyclase

Membrane-bound enzyme that catalyzes formation of cyclic AMP
(cAMP) from ATP; also called adenylyl cyclase. Binding of
certain ligands to their cell-surface receptors leads to activation of
adenylyl cyclase and a rise in intracellular cAMP (Lodish and
others, 2000)

antibody (Ab)

Molecule that reacts with a specific antigen, such as a bacterium
or a toxin, that induced its synthesis or with similar molecules;
destroys or weakens bacteria and neutralizes organic poisons,
forming the basis of immunity; synthesized by B cells that have
been activated by the binding of an antigen to a cell-surface
receptor; also known collectively as immunoglobulins (Ig)

antigen (Ag)

Any of various substances (such as toxins, bacteria, or cells of
transplanted organs) that induce a specific immune response
(production of antibodies) when introduced to the body and can
react or be bound by that specific antibody; named by their ability
to cause antibody generation

antigen-presenting
cell (APC)

Cells that can process antigens and present the fragments on the
cell surface with molecules required for T-cell activation;
dendritic cells, macrophages, and B cells are all capable of serving
as APCs for T cells, but dendritic cells are more specialized and
often synonymous with the term 'professional antigen-presenting
cell' (Janeway and others, 2001)

B cell

A lymphocyte that differentiates into a plasma cell able to
synthesize a specific antibody which will react with the specific
antigen that stimulated the B cell
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Term/Acronym

Definition

cAMP-response
element-binding
(CREB) protein

A transcription factor activated by the catalytic subunit of PKA,
which is activated by cAMP

chemokine

Any of various chemoattractant cytokines produced in
inflammatory response that mobilize and activate cells, especially
phagocytes and lymphocytes (Janeway and others, 2001)

chemotaxis

Movement or orientation of an organism or cell along a chemical
concentration gradient, either toward or away from the stimulus

cyclic adenosine
monophosphate
(cAMP)

An intracellular signaling molecule that increases in concentration
in response to the binding of G protein-coupled receptors,
subsequently activating protein kinase A (PKA) (Lodish and
others, 2000)

cytokine

Any non-antibody protein released on contact with a specific
antigen; acts as an intercellular mediator such as is the generation
of an immune response

cytolysis

The destruction of a cell

cytotoxic

Relating to, or producing a toxic effect on cells

cytotoxic T cell

See T cells; sometimes cytotoxic T leukocyte, or CTL

cytotoxicity

Degree of destructive action by an agent on certain cells

cytotoxin

A T-cell produced protein with a specific toxic effect on target
cells (Janeway and others, 2001)

dendritic cells
(DC)

Immune cells derived from monocytes or from bone marrow
precursors to monocytes; present in skin, lungs, stomach and
intestines in small numbers; constantly sample their surroundings
for pathogens; phagocytose pathogens, digest pathogen proteins,
migrate to lymphoid tissues where they present the protein
fragments on the cell surface and signal to activate lymphocyte
transformation into specific T cells and B cells; mature upon
contact with pathogens, developing dendritic arms for increased
surface area for lymphocyte interaction; known as professional
antigen-presenting cells (APC) (Hart, 1997)
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Term/Acronym

Definition

domain

A tertiary protein structure from folds causing dense clusters of
secondary structures, forming distinct regions on a protein; often
defined by the included amino acids, by a specific motif, or by its
function (catalysis or binding) (Lodish and others, 2000)

endocytosis

Uptake of extracellular material into the cytosol through vesicles
(pores) formed in the plasma membrane (Lodish and others, 2000)

endotoxic shock

Shock associated with overwhelming infection and subsequent
release of endotoxins by gram-negative bacteria that causes
sequestration of blood in the capillaries and veins

endotoxin

Toxin existing as part of the cell membrane of bacteria and
released upon destruction of the bacterial cell; less potent than
exotoxins

fibroblast

Common cell found in connective tissue; secretes collagen and
other components of the extracellular matrix; migrates and
proliferates during wound healing (Lodish and others, 2000)

helper T cell

Lymphocyte that makes lymphokines to regulate other immune
cells, such as B cells and monocytes; "necessary for the
differentiating of B cells into antibody-producing cells"; also Thelper cell, Th cell, or Th1 cell (The American Heritage Stedman’s
Medical Dictionary, 2004)

immunoglobulin
(Ig)

See antibody (Ab); divided into five major classes (IgA, IgD, IgE,
IgG, and IgM) with unique structures and antigenic functions
(Lodish and others, 2000)

inhibitor

Substance that inhibits, reduces or limits physiological, chemical,
or enzymatic action (reaction rate, enzyme catalytic activity,
growth of microorganisms)

innate immunity

Immunity that occurs naturally via physical and biochemical
barriers of the body, such as skin and the mucociliary escalator, as
well as nonspecific immune cells, such as
monocytes/macrophages, neutrophils, and dendritic cells, and
does not arise from an immunologic memory of previous infection
or vaccination (Klaassen and Watkins, 2003)
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Term/Acronym

Definition

interferon

Antiviral glycoprotein cytokine produced in response stimuli,
such as viruses, bacteria or endotoxins, and that binds to receptors
on target cells so as to interfere with viral replication in the cells
and, in some cases, modulate specific cellular immune functions

interleukin (IL)

"Any of a class of lymphokines that act to stimulate, regulate, or
modulate lymphocytes such as T cells" (The American Heritage
Stedman’s Medical Dictionary, 2004)

kinase

Any of various enzymes that transfer a phosphate group from a
donor, such as ADP or ATP, to an acceptor; named for the
acceptor molecule such that a kinase which catalytically
phosphorylates a protein is a protein kinase

leukocyte

Any of various forms of white blood cells, such as lymphocytes,
monocytes, macrophages, and neutrophils, that function as
protection against infection by microorganisms; capable of
amoeboid movement

lipopolysaccharide
(LPS)

an endotoxin derived from Gram-negative bacteria and commonly
used as a macrophage activator, due to its ability to induce a
strong response in immune cells and induce proinflammatory
cytokines in macrophages

lymphocyte

Mononuclear, non-granular white blood cell produced in
lymphoid tissue (lymph nodes, spleen, thymus, tonsils) and
functioning in the development of immunity by transformation to
T cells or B cells; make up 22-28% of white blood cells in
humans

lymphokine

General term for soluble proteins that are released by sensitized
lymphocytes on contact with specific antigens; mediate
transformation of additional lymphocytes and play a role in
monocyte and macrophage activity

macrophage

Any of large, mononuclear, highly phagocytic cells derived from
monocytes that occur in the walls of blood vessels and loose
connective tissue; usually immobile but become actively mobile
when stimulated by inflammation; interact with lymphocytes to
facilitate antibody production

mitogen

Agent that stimulates mitosis and lymphocyte transformation
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Term/Acronym

Definition

monocyte

Large, mononuclear, circulating, phagocytic white blood cell with
fine granulation in the cytoplasm; formed in the bone marrow,
transported to tissues, then develop into macrophages or dendritic
cells; make up 3-8% of white blood cells in humans

motif

In a protein, a specific combination of and three-dimensional
configuration of secondary structures (where primary structure is
the sequence of amino acids in the protein's polypeptide chain,
and secondary structure is a molecular shape such as a helix,
sheet, turn, or loop that is stabilized by hydrogen bonds) (Lodish
and others, 2000; Cooper, 2000)

murine

Of, relating to, or transmitted by a member of the rodent family

natural killer (NK)
cells

Large granular, non-specialized lymphocytes (innate immune
cells, unlike T and B lymphocytes) that detect and kill pathogeninfected cells and certain tumor cells (Janeway and others, 2001)

neutrophil

Granular, highly phagocytic, highly pathogen-destructive white
blood cell playing an important role in killing extracellular
pathogens; "the major class of white blood cell in human
peripheral blood" and responsible for recruiting macrophages if
unable to contain and infection; also known as polymorphonuclear
cells (PMNs) or neutrophilic PMNs (Janeway and others, 2001)

phagocytosis

Process by which extracellular materials, particles or pathogens
are internalized, usually by macrophages or neutrophils; bacteria
are taken up into a vesicle called a phagosome to be destroyed by
lysosomal enzymes (Janeway and others, 2001)

phosphorylation

Addition of a phosphate group to a molecule by a phosphorylase
or kinase, especially in the case of activation of an enzyme by
addition of one or more phosphate groups to specific amino acids

phosphotase

An enzyme that catalytically removes a phosphate group from a
substrate; named for the substrate upon which dephosphorylation
is performed such that a kinase phosphotase removes the
phosphate group from a kinase, thereby deactivating it (Janeway
and others, 2001)
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Term/Acronym

Definition

platelet

Cytoplasmic body having no nucleus or DNA, but having
mitochondria and active enzymes, that is found in blood plasma
and that promotes blood clotting; also called a thrombocyte

protein kinase A
(PKA)

Any of a family of inactive protein kinases which dissociates and
releases two catalytic subunits when bound on regulatory subunits
by cAMP; the released catalytic subunits then phosphorylate
various proteins, including in the nucleus; also known as cAMPdependent protein kinase (cAPK) (Lodish and others, 2000)

T cell

A principal lymphocyte developed in the thymus and transported
in the blood to lymphoid tissues where they have various adapted
immune system roles such as identification of antigens and
activation and deactivation of other immune cells; considered
naïve T cells until they specialize upon exposure to an antigen, at
which time the naive cell can proliferate and differentiate into
cytotoxic T cells, which are capable of killing other cells, or
helper T cells (see definition)

transcription factor

Non-RNA polymerase protein that initiates or regulates gene
transcription (Lodish and others, 2000)

tumor necrosis
factor (TNF)

Cytokine that induces programmed cell death, especially in tumor
cells, but also makes inflammatory disease worse; most often
produced by macrophages in the presence of an endotoxin
(Janeway and others, 2001)

TNF-α

Cytokine with multiple immune functions which is produced by
macrophages and activated T cells; primary member of the TNF
family of cytokines (Janeway and others, 2001)

Ab

Antibody

Ag

Antigen

AM

Alveolar macrophage

APC

Antigen presenting cell

AT

Anthrax toxin
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Term/Acronym

Definition

cAMP

Cyclic adenosine monophosphate; also cyclic AMP

CREB

cAMP-response element-binding (CREB) protein

DC

Dendritic cells

EF

See edema factor

ERK

Extracellular signal-regulated kinase

ET

Edema toxin

LF

Lethal factor

LPS

Lipopolysaccharide

LT

Lethal toxin

MAPK

Mitogen-activated protein kinase

MAPKK

MAPK kinase

MAPKKK

MAPK kinase kinase

MAPK-P

Inactive MAPK with a single phosphate group

MAPK-P'ase

MAPK phosphotase, which dephosphorylates (inactivates) MAPK

MAPK-PP

Dual phosphorylated and thus activated MAPK

NK

Natural killer cells

PKA

Protein kinase A

PA

Protective antigen

TNF

Tumor necrosis factor
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Appendix B: Method for Translating SBML Models

Translation of SBML and JDesigner models into Berkeley Madonna was achieved by
modifying the relevant code using the following procedures. Madonna has help files with
basic instructions on editing and application of equations, such as performing integrations
and using exposure parameters (concentrations, durations, repetitions). A complete
software user guide is also available on the Madonna website.

1. Open a new file in Madonna and, replacing the default code of the new file, paste in
the following:
;Parameters for simulated experiment
length = 12
;Length of inhalation exposure (hrs)
interval = 24
method stiff
;Rosenbrock stiff solver
starttime = 0
stoptime = 24
dtmin = 0.0001
;minimum (and initial) step size
dtmax=1
;maximum step size
tolerance=0.0001
;error tolerance for stiff solver
dtout=0.1
;communication interval (optional)
deltaT = stepsize
;allows plotting step sizes used as
deltaT(optional)
interval = 24

The last two lines allow repeated exposure scenarios to be modeled, such as daily
exposures (24 h interval).
2. In JDesigner, view the model equations (View -> View Model Equations). Cut and
paste from this window into a newly created text file. If necessary, omit (or comment
out) the moiety conservation equations. Changing the equations to comments can be
achieved by placing a semicolon at the start of each line.
3. In JDesigner, select the second ‘Export…’ option from the File drop down menu;
select the Jarnac tab in the resulting window. The ‘Display Translation’ button at the
bottom of the window must be selected to display the code. Cut and paste the code
related to the parameter initial values (the lines beginning with ‘p.’, ignore the model
equations). The “p.compartment = 1;” equation code should be not be included.
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4. Edit the resulting text file according to the following.
a. Replace // with ; to convert comment lines.
b. Replace “p.X = x” with “init X = x”, where X is a chemical parameter and x is its
initial concentration at t = 0. Replace “p.Y = y” with “Y = y”, where Y is a
kinetic reaction constant and y is the value of the constant.
c. Replace “dX/dT” with “ X’ ” (using the prime in Madonna to denote a derivative).
d. Replace “v[X]” with “X”.
e. Some mathematical expressions may also need to be changed. In MichaelisMenten kinetic models, “pow(X,n)” becomes “X^n”.
5. Paste resulting text file into the Madonna file below the code from step one above.
6. Co-ordinate exposure parameters, if necessary.
7. Run the program. By default, Madonna plots the first two variables listed when the
program is run. Other variables can be selected for viewing using the buttons in the
graph window.

Example Translation
This example is based on the oscillating model (Kholodenko, 2000) downloaded from
BioModels and imported into JDesigner for translation into Berkeley Madonna (without
the addition of LF-MAPKK cleavage reactions in JDesigner as described in Chapter III).
The model equations as displayed in JDesigner are:
// Reaction Rates:
v[J0] = uVol*J0_V1*MKKK/((1+pow(MAPK_PP/J0_Ki,J0_n))*(J0_K1+MKKK))
v[J1] = uVol*J1_V2*MKKK_P/(J1_KK2+MKKK_P)
v[J2] = uVol*J2_k3*MKKK_P*MKK/(J2_KK3+MKK)
v[J3] = uVol*J3_k4*MKKK_P*MKK_P/(J3_KK4+MKK_P)
v[J4] = uVol*J4_V5*MKK_PP/(J4_KK5+MKK_PP)
v[J5] = uVol*J5_V6*MKK_P/(J5_KK6+MKK_P)
v[J6] = uVol*J6_k7*MKK_PP*MAPK/(J6_KK7+MAPK)
v[J7] = uVol*J7_k8*MKK_PP*MAPK_P/(J7_KK8+MAPK_P)
v[J8] = uVol*J8_V9*MAPK_PP/(J8_KK9+MAPK_PP)
v[J9] = uVol*J9_V10*MAPK_P/(J9_KK10+MAPK_P)
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// Differential Equations:
dMKKK/dt = - J0 + J1
dMKK/dt = - J2 + J5
dMKK_P/dt = + J2 - J3 + J4 - J5
dMAPK/dt = - J6 + J9
dMAPK_P/dt = + J6 - J7 + J8 - J9
dMKKK_P/dt = + J0 - J1
dMKK_PP/dt = + J3 - J4
dMAPK_PP/dt = + J7 - J8
// Conservation Laws:
1: MKKK + MKKK_P
2: MKK + MKK_P + MKK_PP
3: MAPK + MAPK_P + MAPK_PP

The parameter values (excluding p.compartment) from the exported Jarnac script are:
p.uVol = 1;
p.MKKK = 90;
p.MKKK_P = 10;
p.MKK = 280;
p.MKK_P = 10;
p.MKK_PP = 10;
p.MAPK = 280;
p.MAPK_P = 10;
p.MAPK_PP = 10;
p.J0_V1 = 2.5;
p.J0_Ki = 9;
p.J0_n = 1;
p.J0_K1 = 10;
p.J1_V2 = 0.25;
p.J1_KK2 = 8;
p.J2_k3 = 0.025;
p.J2_KK3 = 15;
p.J3_k4 = 0.025;
p.J3_KK4 = 15;
p.J4_V5 = 0.75;
p.J4_KK5 = 15;
p.J5_V6 = 0.75;
p.J5_KK6 = 15;
p.J6_k7 = 0.025;
p.J6_KK7 = 15;
p.J7_k8 = 0.025;
p.J7_KK8 = 15;
p.J8_V9 = 0.5;
p.J8_KK9 = 15;
p.J9_V10 = 0.5;
p.J9_KK10 = 15;
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The final Madonna file, after editing, looks like the following:
; Parameters for simulated experiment
method stiff
;Rosenbrock stiff solver
starttime = 0
stoptime = 24
dtmin = 0.0001 ;minimum (and initial) step size
dtmax=1
;maximum step size
tolerance=0.0001
;error tolerance for stiff solver
dtout=0.1
;communication interval (optional)
; Reaction Rates:
J0 = uVol*J0_V1*MKKK/((1+(MAPK_PP/J0_Ki)^(J0_n))*(J0_K1+MKKK))
J1 = uVol*J1_V2*MKKK_P/(J1_KK2+MKKK_P)
J2 = uVol*J2_k3*MKKK_P*MKK/(J2_KK3+MKK)
J3 = uVol*J3_k4*MKKK_P*MKK_P/(J3_KK4+MKK_P)
J4 = uVol*J4_V5*MKK_PP/(J4_KK5+MKK_PP)
J5 = uVol*J5_V6*MKK_P/(J5_KK6+MKK_P)
J6 = uVol*J6_k7*MKK_PP*MAPK/(J6_KK7+MAPK)
J7 = uVol*J7_k8*MKK_PP*MAPK_P/(J7_KK8+MAPK_P)
J8 = uVol*J8_V9*MAPK_PP/(J8_KK9+MAPK_PP)
J9 = uVol*J9_V10*MAPK_P/(J9_KK10+MAPK_P)
J10 = J10_KX*MKK
; Differential Equations:
MKKK’ = - J0 + J1
MKK’ = - J2 + J5 - J10
MKK_P’ = + J2 - J3 + J4 - J5
MKK_PP’ = + J3 - J4
MAPK’ = - J6 + J9
MAPK_P’ = + J6 - J7 + J8 - J9
MKKK_P’ = + J0 - J1
MAPK_PP’ = + J7 - J8
Cleaved_MKK’ = + J10
; Initial values
init uVol = 1;
init MKKK = 90;
init MKKK_P = 10;
init MKK = 280;
init MKK_P = 10;
init MKK_PP = 10;
init MAPK = 280;
init MAPK_P = 10;
init MAPK_PP = 10;
init Cleaved_MKK = 0;
J0_V1 = 2.5;
J0_Ki = 9;
J0_n = 1;
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J0_K1 = 10;
J1_V2 = 0.25;
J1_KK2 = 8;
J2_k3 = 0.025;
J2_KK3 = 15;
J3_k4 = 0.025;
J3_KK4 = 15;
J4_V5 = 0.75;
J4_KK5 = 15;
J5_V6 = 0.75;
J5_KK6 = 15;
J6_k7 = 0.025;
J6_KK7 = 15;
J7_k8 = 0.025;
J7_KK8 = 15;
J8_V9 = 0.5;
J8_KK9 = 15;
J9_V10 = 0.5;
J9_KK10 = 15;
J10_KX = 0.00025;
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Appendix C: Berkeley Madonna Code for Models

Each model was converted to code able to be imported into Berkeley Madonna
(version 8.3.11) following the procedures in Appendix B. This appendix includes the
code for each model as exported from Berkeley Madonna; while parameter values were
varied according to the discussion in Chapters III and IV, the code included here reflects
only one value per parameter.

Ultrasensitivity Model
; Huang (3 RXN) with LF cleavage of MAPKK, _P, and _PP
; Parameters for simulated experiment
method stiff
;Rosenbrock stiff solver
starttime = 0
stoptime = 54000
dtmin = 0.1
;minimum (and initial) step size
dtmax=5
;maximum step size
tolerance=0.0001
;error tolerance for stiff solver
dtout=5
;communication interval, optional (included to alleviate insufficient memory errors)
; Initial values
init PP_K = 0;
init Cleaved_MAPKKs = 0;
init E1 = 3E-05;
init E2 = 0.0003;
init KKK = 0.003;
init P_KKK = 0;
init KK = 1.2;
init P_KK = 0;
init PP_KK = 0;
init K = 1.2;
init P_K = 0;
init KPase = 0.12;
init KKPase = 0.0003;
init E1_KKK = 0;
init E2_P_KKK = 0;
init P_KKK_KK = 0;
init P_KKK_P_KK = 0;
init PP_KK_K = 0;
init PP_KK_P_K = 0;
init KKPase_PP_KK = 0;
init KKPase_P_KK = 0;
init KPase_PP_K = 0;
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init KPase_P_K = 0;
r1a_a1 = 1000;
r1a_d1 = 150;
r1b_k2 = 150;
r2a_a2 = 1000;
r2a_d2 = 150;
r2b_k2 = 150;
r3a_a3 = 1000;
r3a_d3 = 150;
r3b_k3 = 150;
r4a_a4 = 1000;
r4a_d4 = 150;
r4b_k4 = 150;
r5a_a5 = 1000;
r5a_d5 = 150;
r5b_k5 = 150;
r6a_a6 = 1000;
r6a_d6 = 150;
r6b_k6 = 150;
r7a_a7 = 1000;
r7a_d7 = 150;
r7b_k7 = 150;
r8a_a8 = 1000;
r8a_d8 = 150;
r8b_k8 = 150;
r9a_a9 = 1000;
r9a_d9 = 150;
r9b_k9 = 150;
r10a_a10 = 1000;
r10a_d10 = 150;
r10b_k10 = 150;
J20_k = 0.000295; MKK cleavage
J21_k = 0.000295; MKK_P cleavage
J22_k = 0.000295; MKK_PP cleavage
compartment = 1;
; Reaction Rates:
r1a = compartment*(r1a_a1*E1*KKK-r1a_d1*E1_KKK)
r1b = compartment*r1b_k2*E1_KKK
r2a = compartment*(r2a_a2*E2*P_KKK-r2a_d2*E2_P_KKK)
r2b = compartment*r2b_k2*E2_P_KKK
r3a = compartment*(r3a_a3*KK*P_KKK-r3a_d3*P_KKK_KK)
r3b = compartment*r3b_k3*P_KKK_KK
r4a = compartment*(r4a_a4*P_KK*KKPase-r4a_d4*KKPase_P_KK)
r4b = compartment*r4b_k4*KKPase_P_KK
r5a = compartment*(r5a_a5*P_KK*P_KKK-r5a_d5*P_KKK_P_KK)
r5b = compartment*r5b_k5*P_KKK_P_KK
r6a = compartment*(r6a_a6*PP_KK*KKPase-r6a_d6*KKPase_PP_KK)
r6b = compartment*r6b_k6*KKPase_PP_KK
r7a = compartment*(r7a_a7*K*PP_KK-r7a_d7*PP_KK_K)
r7b = compartment*r7b_k7*PP_KK_K
r8a = compartment*(r8a_a8*P_K*KPase-r8a_d8*KPase_P_K)
r8b = compartment*r8b_k8*KPase_P_K
r9a = compartment*(r9a_a9*P_K*PP_KK-r9a_d9*PP_KK_P_K)
r9b = compartment*r9b_k9*PP_KK_P_K
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r10a = compartment*(r10a_a10*PP_K*KPase-r10a_d10*KPase_PP_K)
r10b = compartment*r10b_k10*KPase_PP_K
J20 = J20_k*KK
J21 = J21_k*P_KK
J22 = J22_k*PP_KK
; Differential Equations:
E1' = - r1a + r1b
E2' = - r2a + r2b
KKK' = - r1a + r2b
P_KKK' = + r1b - r2a - r3a + r3b - r5a + r5b
KK' = - r3a + r4b - J20
P_KK' = + r3b - r4a - r5a + r6b - J21
PP_KK' = + r5b - r6a - r7a + r7b - r9a + r9b - J22
K' = - r7a + r8b
P_K' = + r7b - r8a - r9a + r10b
PP_K' = + r9b - r10a
KPase' = - r8a + r8b - r10a + r10b
KKPase' = - r4a + r4b - r6a + r6b
P_KKK_KK' = + r3a - r3b
PP_KK_K' = + r7a - r7b
KKPase_PP_KK' = + r6a - r6b
KPase_PP_K' = + r10a - r10b
E2_P_KKK' = + r2a - r2b
PP_KK_P_K' = + r9a - r9b
E1_KKK' = + r1a - r1b
KKPase_P_KK' = + r4a - r4b
P_KKK_P_KK' = + r5a - r5b
KPase_P_K' = + r8a - r8b
Cleaved_MAPKKs' = + J20 + J21 + J22

Oscillating Negative Feedback Model
; LF cleavage of MAPKK, MAPKK-P, and MAPK-PP (Kholodenko, 2000)
; Parameters for simulated experiment
method stiff
;Rosenbrock stiff solver
starttime = 0
stoptime = 72000
dtmin = 0.0001
;minimum (and initial) step size
dtmax=1
;maximum step size
tolerance=0.0001
;error tolerance for stiff solver
dtout=0.1
;communication interval (optional)
; Initial values of enzymes and assigned values of kinetic constants
init MAPK_PP = 10;
init Cleaved_MKK = 0;
init MKKK = 90;
init MKKK_P = 10;
init MKK = 280;
init MKK_P = 10;
init MKK_PP = 10;
init MAPK = 280;
init MAPK_P = 10;
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uVol = 1;
J0_V1 = 2.5;
J0_Ki = 9;
J0_n = 1
; n = 2 for cooperative inhibition by double phosphorylation of SOS by MAPK
J0_K1 = 10;
J1_V2 = 0.25;
J1_KK2 = 8;
J2_k3 = 0.025;
J2_KK3 = 15;
J3_k4 = 0.025;
J3_KK4 = 15;
J4_V5 = 0.75;
J4_KK5 = 15;
J5_V6 = 0.75;
J5_KK6 = 15;
J6_k7 = 0.025;
J6_KK7 = 15;
J7_k8 = 0.025;
J7_KK8 = 15;
J8_V9 = 0.5;
J8_KK9 = 15;
J9_V10 = 0.5;
J9_KK10 = 15;
J10_KK = 0.00015
; kinetic constant (k) for LF cleavage of MAPKK
J11_KK_P = 0.00015
; kinetic constant (k) for LF cleavage of MAPKK-P
J12_KK_PP = 0.00015
; kinetic constant (k) for LF cleavage of MAPKK-PP
; Reaction Rates:
J0 = uVol*J0_V1*MKKK/((1+(MAPK_PP/J0_Ki)^(J0_n))*(J0_K1+MKKK))
J1 = uVol*J1_V2*MKKK_P/(J1_KK2+MKKK_P)
J2 = uVol*J2_k3*MKKK_P*MKK/(J2_KK3+MKK)
J3 = uVol*J3_k4*MKKK_P*MKK_P/(J3_KK4+MKK_P)
J4 = uVol*J4_V5*MKK_PP/(J4_KK5+MKK_PP)
J5 = uVol*J5_V6*MKK_P/(J5_KK6+MKK_P)
J6 = uVol*J6_k7*MKK_PP*MAPK/(J6_KK7+MAPK)
J7 = uVol*J7_k8*MKK_PP*MAPK_P/(J7_KK8+MAPK_P)
J8 = uVol*J8_V9*MAPK_PP/(J8_KK9+MAPK_PP)
J9 = uVol*J9_V10*MAPK_P/(J9_KK10+MAPK_P)
J10 = J10_KK*MKK
; LF cleavage of MAPKK
J11 = J11_KK_P*MKK_P
; LF cleavage of MAPKK-P
J12 = J12_KK_PP*MKK_PP
; LF cleavage of MAPKK-PP
; Differential Equations:
MKKK' = - J0 + J1
MKK' = - J2 + J5 - J10
MKK_P' = + J2 - J3 + J4 - J5 - J11
MKK_PP' = + J3 - J4 - J12
MAPK' = - J6 + J9
MAPK_P' = + J6 - J7 + J8 - J9
MKKK_P' = + J0 - J1
MAPK_PP' = + J7 - J8
Cleaved_MKK' = + J10 + J11 + J12
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Scaffold Proteins Model
; MAPK cascade with Scaffold protein, with LF cleavage of MAPKK, -P and -PP (non scaffold)
; (Levchenko and others, 2000)
;Parameters for simulated experiment
method stiff
;Rosenbrock stiff solver
starttime = 0
stoptime = 54000
dtmin = 0.0001
;minimum (and initial) step size
dtmax=2
;maximum step size
tolerance=0.0001
;error tolerance for stiff solver
dtout=1
;communication interval (optional)
; Initial parameter values
init K_1_2 = 0;
init Cleaved_MAPKK = 0;
init MAPKP = 0.3;
init MEKP = 0.2;
init RAFK = 0.1;
init RAFP = 0.3;
init K_1_0 = 0.4;
init K_1_1 = 0;
init K_2_0 = 0.2;
init K_2_1 = 0;
init K_2_2 = 0;
init K_3_0 = 0.3;
init K_3_1 = 0;
init K_K_1_0_2_2 = 0;
init K_K_1_1_2_2 = 0;
init K_K_2_0_3_1 = 0;
init K_K_2_1_3_1 = 0;
init K_MAPKP_1_1 = 0;
init K_MAPKP_1_2 = 0;
init K_MEKP_2_1 = 0;
init K_MEKP_2_2 = 0;
init K_RAFK_3_0 = 0;
init K_RAFP_3_1 = 0;
init S_m1_m1_m1 = 0.1;
init S_m1_m1_0 = 0;
init S_m1_m1_1 = 0;
init S_m1_0_m1 = 0;
init S_m1_0_0 = 0;
init S_m1_0_1 = 0;
init S_m1_1_m1 = 0;
init S_m1_1_0 = 0;
init S_m1_1_1 = 0;
init S_m1_2_m1 = 0;
init S_m1_2_0 = 0;
init S_m1_2_1 = 0;
init S_0_m1_m1 = 0;
init S_0_m1_0 = 0;
init S_0_m1_1 = 0;
init S_0_0_m1 = 0;
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init S_0_0_0 = 0;
init S_0_0_1 = 0;
init S_0_1_m1 = 0;
init S_0_1_0 = 0;
init S_0_1_1 = 0;
init S_0_2_m1 = 0;
init S_0_2_0 = 0;
init S_0_2_1 = 0;
init S_1_m1_m1 = 0;
init S_1_m1_0 = 0;
init S_1_m1_1 = 0;
init S_1_0_m1 = 0;
init S_1_0_0 = 0;
init S_1_0_1 = 0;
init S_1_1_m1 = 0;
init S_1_1_0 = 0;
init S_1_1_1 = 0;
init S_1_2_m1 = 0;
init S_1_2_0 = 0;
init S_1_2_1 = 0;
init S_2_m1_m1 = 0;
init S_2_m1_0 = 0;
init S_2_m1_1 = 0;
init S_2_0_m1 = 0;
init S_2_0_0 = 0;
init S_2_0_1 = 0;
init S_2_1_m1 = 0;
init S_2_1_0 = 0;
init S_2_1_1 = 0;
init S_2_2_m1 = 0;
init S_2_2_0 = 0;
init S_2_2_1 = 0;
init S_RAFK_m1_m1_0 = 0;
init S_RAFK_m1_0_0 = 0;
init S_RAFK_m1_1_0 = 0;
init S_RAFK_m1_2_0 = 0;
init S_RAFK_0_m1_0 = 0;
init S_RAFK_0_0_0 = 0;
init S_RAFK_0_1_0 = 0;
init S_RAFK_0_2_0 = 0;
init S_RAFK_1_m1_0 = 0;
init S_RAFK_1_0_0 = 0;
init S_RAFK_1_1_0 = 0;
init S_RAFK_1_2_0 = 0;
init S_RAFK_2_m1_0 = 0;
init S_RAFK_2_0_0 = 0;
init S_RAFK_2_1_0 = 0;
init S_RAFK_2_2_0 = 0;
J302_KK_k = 0.00059
J301_KKP_k = 0.00059
J303_KKPP_k = 0.00059
Cytoplasm = 1;
Reaction1_a1 = 1;
Reaction2_d1 = 0.4;

; LF cleavage of MAPKK
; LF cleavage of MAPKK-P
; LF cleavage of MAPKK-PP
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Reaction3_k1 = 0.1;
Reaction4_a2 = 0.5;
Reaction5_d2 = 0.5;
Reaction6_k2 = 0.1;
Reaction7_a3 = 3.3;
Reaction8_d3 = 0.42;
Reaction9_k3 = 0.1;
Reaction10_a4 = 10;
Reaction11_d4 = 0.8;
Reaction12_k4 = 0.1;
Reaction13_a5 = 3.3;
Reaction14_d5 = 0.4;
Reaction15_k5 = 0.1;
Reaction16_a6 = 10;
Reaction17_d6 = 0.8;
Reaction18_k6 = 0.1;
Reaction19_a7 = 20;
Reaction20_d7 = 0.6;
Reaction21_k7 = 0.1;
Reaction22_a8 = 5;
Reaction23_d8 = 0.4;
Reaction24_k8 = 0.1;
Reaction25_a9 = 20;
Reaction26_d9 = 0.6;
Reaction27_k9 = 0.1;
Reaction28_a10 = 5;
Reaction29_d10 = 0.4;
Reaction30_k10 = 0.1;
Reaction31_kon = 10;
Reaction32_koff = 0.5;
Reaction33_kon = 10;
Reaction34_koff = 0.5;
Reaction35_kon = 10;
Reaction36_koff = 0.5;
Reaction37_kon = 10;
Reaction38_koff = 0.5;
Reaction39_kon = 10;
Reaction40_koff = 0.5;
Reaction41_kon = 10;
Reaction42_koff = 0.5;
Reaction43_kon = 10;
Reaction44_koff = 0.5;
Reaction45_kon = 10;
Reaction46_koff = 0.5;
Reaction47_kon = 10;
Reaction48_koff = 0.5;
Reaction49_kon = 10;
Reaction50_koff = 0.5;
Reaction51_kon = 10;
Reaction52_koff = 0.5;
Reaction53_kon = 10;
Reaction54_koff = 0.5;
Reaction55_kpon = 0;
Reaction56_kpoff = 0.05;
Reaction57_kpon = 0;
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Reaction58_kpoff = 0.05;
Reaction59_kpon = 0;
Reaction60_kpoff = 0.05;
Reaction61_kpon = 0;
Reaction62_kpoff = 0.05;
Reaction63_kpon = 0;
Reaction64_kpoff = 0.05;
Reaction65_kpon = 0;
Reaction66_kpoff = 0.05;
Reaction67_kpon = 0;
Reaction68_kpoff = 0.05;
Reaction69_kpon = 0;
Reaction70_kpoff = 0.05;
Reaction71_kpon = 0;
Reaction72_kpoff = 0.05;
Reaction73_kpon = 0;
Reaction74_kpoff = 0.05;
Reaction75_kpon = 0;
Reaction76_kpoff = 0.05;
Reaction77_kpon = 0;
Reaction78_kpoff = 0.05;
Reaction79_kpon = 0;
Reaction80_kpoff = 0.05;
Reaction81_kpon = 0;
Reaction82_kpoff = 0.05;
Reaction83_kpon = 0;
Reaction84_kpoff = 0.05;
Reaction85_kpon = 0;
Reaction86_kpoff = 0.05;
Reaction87_kpon = 0;
Reaction88_kpoff = 0.05;
Reaction89_kpon = 0;
Reaction90_kpoff = 0.05;
Reaction91_kpon = 0;
Reaction92_kpoff = 0.05;
Reaction93_kpon = 0;
Reaction94_kpoff = 0.05;
Reaction95_kpon = 0;
Reaction96_kpoff = 0.05;
Reaction97_kpon = 0;
Reaction98_kpoff = 0.05;
Reaction99_kpon = 0;
Reaction100_kpoff = 0.05;
Reaction101_kpon = 0;
Reaction102_kpoff = 0.05;
Reaction103_kon = 10;
Reaction104_koff = 0.5;
Reaction105_kon = 10;
Reaction106_koff = 0.5;
Reaction107_kon = 10;
Reaction108_koff = 0.5;
Reaction109_kpon = 0;
Reaction110_kpoff = 0.05;
Reaction111_kpon = 0;
Reaction112_kpoff = 0.05;
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Reaction113_kpon = 0;
Reaction114_kpoff = 0.05;
Reaction115_kpon = 0;
Reaction116_kpoff = 0.05;
Reaction117_kpon = 0;
Reaction118_kpoff = 0.05;
Reaction119_kpon = 0;
Reaction120_kpoff = 0.05;
Reaction121_kon = 10;
Reaction122_koff = 0.5;
Reaction123_kon = 10;
Reaction124_koff = 0.5;
Reaction125_kon = 10;
Reaction126_koff = 0.5;
Reaction127_kpon = 0;
Reaction128_kpoff = 0.05;
Reaction129_kpon = 0;
Reaction130_kpoff = 0.05;
Reaction131_kpon = 0;
Reaction132_kpoff = 0.05;
Reaction133_kpon = 0;
Reaction134_kpoff = 0.05;
Reaction135_kpon = 0;
Reaction136_kpoff = 0.05;
Reaction137_kpon = 0;
Reaction138_kpoff = 0.05;
Reaction139_kon = 10;
Reaction140_koff = 0.5;
Reaction141_kon = 10;
Reaction142_koff = 0.5;
Reaction143_kon = 10;
Reaction144_koff = 0.5;
Reaction145_kpon = 0;
Reaction146_kpoff = 0.05;
Reaction147_kpon = 0;
Reaction148_kpoff = 0.05;
Reaction149_kpon = 0;
Reaction150_kpoff = 0.05;
Reaction151_kpon = 0;
Reaction152_kpoff = 0.05;
Reaction153_kpon = 0;
Reaction154_kpoff = 0.05;
Reaction155_kpon = 0;
Reaction156_kpoff = 0.05;
Reaction157_kon = 10;
Reaction158_koff = 0.5;
Reaction159_kon = 10;
Reaction160_koff = 0.5;
Reaction161_kon = 10;
Reaction162_koff = 0.5;
Reaction163_kpon = 0;
Reaction164_kpoff = 0.05;
Reaction165_kpon = 0;
Reaction166_kpoff = 0.05;
Reaction167_kpon = 0;
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Reaction168_kpoff = 0.05;
Reaction169_kpon = 0;
Reaction170_kpoff = 0.05;
Reaction171_kpon = 0;
Reaction172_kpoff = 0.05;
Reaction173_kpon = 0;
Reaction174_kpoff = 0.05;
Reaction175_kon = 10;
Reaction176_koff = 0.5;
Reaction177_kpon = 0;
Reaction178_kpoff = 0.05;
Reaction179_kon = 10;
Reaction180_koff = 0.5;
Reaction181_kpon = 0;
Reaction182_kpoff = 0.05;
Reaction183_kon = 10;
Reaction184_koff = 0.5;
Reaction185_kpon = 0;
Reaction186_kpoff = 0.05;
Reaction187_kon = 10;
Reaction188_koff = 0.5;
Reaction189_kpon = 0;
Reaction190_kpoff = 0.05;
Reaction191_kon = 10;
Reaction192_koff = 0.5;
Reaction193_kpon = 0;
Reaction194_kpoff = 0.05;
Reaction195_kon = 10;
Reaction196_koff = 0.5;
Reaction197_kpon = 0;
Reaction198_kpoff = 0.05;
Reaction199_kon = 10;
Reaction200_koff = 0.5;
Reaction201_kpon = 0;
Reaction202_kpoff = 0.05;
Reaction203_kon = 10;
Reaction204_koff = 0.5;
Reaction205_kpon = 0;
Reaction206_kpoff = 0.05;
Reaction207_kon = 10;
Reaction208_koff = 0.5;
Reaction209_kpon = 0;
Reaction210_kpoff = 0.05;
Reaction211_kon = 10;
Reaction212_koff = 0.5;
Reaction213_kpon = 0;
Reaction214_kpoff = 0.05;
Reaction215_kon = 10;
Reaction216_koff = 0.5;
Reaction217_kpon = 0;
Reaction218_kpoff = 0.05;
Reaction219_kon = 10;
Reaction220_koff = 0.5;
Reaction221_kpon = 0;
Reaction222_kpoff = 0.05;

98

Reaction223_kon = 10;
Reaction224_koff = 0.5;
Reaction225_kpon = 0;
Reaction226_kpoff = 0.05;
Reaction227_kon = 10;
Reaction228_koff = 0.5;
Reaction229_kpon = 0;
Reaction230_kpoff = 0.05;
Reaction231_kon = 10;
Reaction232_koff = 0.5;
Reaction233_kpon = 0;
Reaction234_kpoff = 0.05;
Reaction235_kon = 10;
Reaction236_koff = 0.5;
Reaction237_kpon = 0;
Reaction238_kpoff = 0.05;
Reaction239_k7 = 0.1;
Reaction240_k7 = 0.1;
Reaction241_k7 = 0.1;
Reaction242_k9a = 0.1;
Reaction243_k9a = 0.1;
Reaction244_k9a = 0.1;
Reaction245_k3 = 0.1;
Reaction246_k5a = 0.1;
Reaction247_k3 = 0.1;
Reaction248_k5a = 0.1;
Reaction249_k3 = 0.1;
Reaction250_k5a = 0.1;
Reaction251_k3 = 0.1;
Reaction252_k5a = 0.1;
Reaction253_k1a = 100;
Reaction254_d1a = 0;
Reaction255_k1 = 0.1;
Reaction256_k1a = 100;
Reaction257_d1a = 0;
Reaction258_k1 = 0.1;
Reaction259_k1a = 100;
Reaction260_d1a = 0;
Reaction261_k1 = 0.1;
Reaction262_k1a = 100;
Reaction263_d1a = 0;
Reaction264_k1 = 0.1;
Reaction265_k1a = 100;
Reaction266_d1a = 0;
Reaction267_k1 = 0.1;
Reaction268_k1a = 100;
Reaction269_d1a = 0;
Reaction270_k1 = 0.1;
Reaction271_k1a = 100;
Reaction272_d1a = 0;
Reaction273_k1 = 0.1;
Reaction274_k1a = 100;
Reaction275_d1a = 0;
Reaction276_k1 = 0.1;
Reaction277_k1a = 100;
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Reaction278_d1a = 0;
Reaction279_k1 = 0.1;
Reaction280_k1a = 100;
Reaction281_d1a = 0;
Reaction282_k1 = 0.1;
Reaction283_k1a = 100;
Reaction284_d1a = 0;
Reaction285_k1 = 0.1;
Reaction286_k1a = 100;
Reaction287_d1a = 0;
Reaction288_k1 = 0.1;
Reaction289_k1a = 100;
Reaction290_d1a = 0;
Reaction291_k1 = 0.1;
Reaction292_k1a = 100;
Reaction293_d1a = 0;
Reaction294_k1 = 0.1;
Reaction295_k1a = 100;
Reaction296_d1a = 0;
Reaction297_k1 = 0.1;
Reaction298_k1a = 100;
Reaction299_d1a = 0;
Reaction300_k1 = 0.1;
; Reaction Rates:
Reaction1 = Reaction1_a1*RAFK*K_3_0
Reaction2 = Reaction2_d1*K_RAFK_3_0
Reaction3 = Reaction3_k1*K_RAFK_3_0
Reaction4 = Reaction4_a2*RAFP*K_3_1
Reaction5 = Reaction5_d2*K_RAFP_3_1
Reaction6 = Reaction6_k2*K_RAFP_3_1
Reaction7 = Reaction7_a3*K_2_0*K_3_1
Reaction8 = Reaction8_d3*K_K_2_0_3_1
Reaction9 = Reaction9_k3*K_K_2_0_3_1
Reaction10 = Reaction10_a4*MEKP*K_2_1
Reaction11 = Reaction11_d4*K_MEKP_2_1
Reaction12 = Reaction12_k4*K_MEKP_2_1
Reaction13 = Reaction13_a5*K_2_1*K_3_1
Reaction14 = Reaction14_d5*K_K_2_1_3_1
Reaction15 = Reaction15_k5*K_K_2_1_3_1
Reaction16 = Reaction16_a6*MEKP*K_2_2
Reaction17 = Reaction17_d6*K_MEKP_2_2
Reaction18 = Reaction18_k6*K_MEKP_2_2
Reaction19 = Reaction19_a7*K_1_0*K_2_2
Reaction20 = Reaction20_d7*K_K_1_0_2_2
Reaction21 = Reaction21_k7*K_K_1_0_2_2
Reaction22 = Reaction22_a8*MAPKP*K_1_1
Reaction23 = Reaction23_d8*K_MAPKP_1_1
Reaction24 = Reaction24_k8*K_MAPKP_1_1
Reaction25 = Reaction25_a9*K_1_1*K_2_2
Reaction26 = Reaction26_d9*K_K_1_1_2_2
Reaction27 = Reaction27_k9*K_K_1_1_2_2
Reaction28 = Reaction28_a10*MAPKP*K_1_2
Reaction29 = Reaction29_d10*K_MAPKP_1_2
Reaction30 = Reaction30_k10*K_MAPKP_1_2
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Reaction31 = Reaction31_kon*K_1_0*S_m1_m1_m1
Reaction32 = Reaction32_koff*S_0_m1_m1
Reaction33 = Reaction33_kon*K_1_0*S_m1_m1_0
Reaction34 = Reaction34_koff*S_0_m1_0
Reaction35 = Reaction35_kon*K_1_0*S_m1_m1_1
Reaction36 = Reaction36_koff*S_0_m1_1
Reaction37 = Reaction37_kon*K_1_0*S_m1_0_m1
Reaction38 = Reaction38_koff*S_0_0_m1
Reaction39 = Reaction39_kon*K_1_0*S_m1_0_0
Reaction40 = Reaction40_koff*S_0_0_0
Reaction41 = Reaction41_kon*K_1_0*S_m1_0_1
Reaction42 = Reaction42_koff*S_0_0_1
Reaction43 = Reaction43_kon*K_1_0*S_m1_1_m1
Reaction44 = Reaction44_koff*S_0_1_m1
Reaction45 = Reaction45_kon*K_1_0*S_m1_1_0
Reaction46 = Reaction46_koff*S_0_1_0
Reaction47 = Reaction47_kon*K_1_0*S_m1_1_1
Reaction48 = Reaction48_koff*S_0_1_1
Reaction49 = Reaction49_kon*K_1_0*S_m1_2_m1
Reaction50 = Reaction50_koff*S_0_2_m1
Reaction51 = Reaction51_kon*K_1_0*S_m1_2_0
Reaction52 = Reaction52_koff*S_0_2_0
Reaction53 = Reaction53_kon*K_1_0*S_m1_2_1
Reaction54 = Reaction54_koff*S_0_2_1
Reaction55 = Reaction55_kpon*K_1_1*S_m1_m1_m1
Reaction56 = Reaction56_kpoff*S_1_m1_m1
Reaction57 = Reaction57_kpon*K_1_1*S_m1_m1_0
Reaction58 = Reaction58_kpoff*S_1_m1_0
Reaction59 = Reaction59_kpon*K_1_1*S_m1_m1_1
Reaction60 = Reaction60_kpoff*S_1_m1_1
Reaction61 = Reaction61_kpon*K_1_1*S_m1_0_m1
Reaction62 = Reaction62_kpoff*S_1_0_m1
Reaction63 = Reaction63_kpon*K_1_1*S_m1_0_0
Reaction64 = Reaction64_kpoff*S_1_0_0
Reaction65 = Reaction65_kpon*K_1_1*S_m1_0_1
Reaction66 = Reaction66_kpoff*S_1_0_1
Reaction67 = Reaction67_kpon*K_1_1*S_m1_1_m1
Reaction68 = Reaction68_kpoff*S_1_1_m1
Reaction69 = Reaction69_kpon*K_1_1*S_m1_1_0
Reaction70 = Reaction70_kpoff*S_1_1_0
Reaction71 = Reaction71_kpon*K_1_1*S_m1_1_1
Reaction72 = Reaction72_kpoff*S_1_1_1
Reaction73 = Reaction73_kpon*K_1_1*S_m1_2_m1
Reaction74 = Reaction74_kpoff*S_1_2_m1
Reaction75 = Reaction75_kpon*K_1_1*S_m1_2_0
Reaction76 = Reaction76_kpoff*S_1_2_0
Reaction77 = Reaction77_kpon*K_1_1*S_m1_2_1
Reaction78 = Reaction78_kpoff*S_1_2_1
Reaction79 = Reaction79_kpon*K_1_2*S_m1_m1_m1
Reaction80 = Reaction80_kpoff*S_2_m1_m1
Reaction81 = Reaction81_kpon*K_1_2*S_m1_m1_0
Reaction82 = Reaction82_kpoff*S_2_m1_0
Reaction83 = Reaction83_kpon*K_1_2*S_m1_m1_1
Reaction84 = Reaction84_kpoff*S_2_m1_1
Reaction85 = Reaction85_kpon*K_1_2*S_m1_0_m1
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Reaction86 = Reaction86_kpoff*S_2_0_m1
Reaction87 = Reaction87_kpon*K_1_2*S_m1_0_0
Reaction88 = Reaction88_kpoff*S_2_0_0
Reaction89 = Reaction89_kpon*K_1_2*S_m1_0_1
Reaction90 = Reaction90_kpoff*S_2_0_1
Reaction91 = Reaction91_kpon*K_1_2*S_m1_1_m1
Reaction92 = Reaction92_kpoff*S_2_1_m1
Reaction93 = Reaction93_kpon*K_1_2*S_m1_1_0
Reaction94 = Reaction94_kpoff*S_2_1_0
Reaction95 = Reaction95_kpon*K_1_2*S_m1_1_1
Reaction96 = Reaction96_kpoff*S_2_1_1
Reaction97 = Reaction97_kpon*K_1_2*S_m1_2_m1
Reaction98 = Reaction98_kpoff*S_2_2_m1
Reaction99 = Reaction99_kpon*K_1_2*S_m1_2_0
Reaction100 = Reaction100_kpoff*S_2_2_0
Reaction101 = Reaction101_kpon*K_1_2*S_m1_2_1
Reaction102 = Reaction102_kpoff*S_2_2_1
Reaction103 = Reaction103_kon*K_2_0*S_m1_m1_m1
Reaction104 = Reaction104_koff*S_m1_0_m1
Reaction105 = Reaction105_kon*K_2_0*S_m1_m1_0
Reaction106 = Reaction106_koff*S_m1_0_0
Reaction107 = Reaction107_kon*K_2_0*S_m1_m1_1
Reaction108 = Reaction108_koff*S_m1_0_1
Reaction109 = Reaction109_kpon*K_2_1*S_m1_m1_m1
Reaction110 = Reaction110_kpoff*S_m1_1_m1
Reaction111 = Reaction111_kpon*K_2_1*S_m1_m1_0
Reaction112 = Reaction112_kpoff*S_m1_1_0
Reaction113 = Reaction113_kpon*K_2_1*S_m1_m1_1
Reaction114 = Reaction114_kpoff*S_m1_1_1
Reaction115 = Reaction115_kpon*K_2_2*S_m1_m1_m1
Reaction116 = Reaction116_kpoff*S_m1_2_m1
Reaction117 = Reaction117_kpon*K_2_2*S_m1_m1_0
Reaction118 = Reaction118_kpoff*S_m1_2_0
Reaction119 = Reaction119_kpon*K_2_2*S_m1_m1_1
Reaction120 = Reaction120_kpoff*S_m1_2_1
Reaction121 = Reaction121_kon*K_2_0*S_0_m1_m1
Reaction122 = Reaction122_koff*S_0_0_m1
Reaction123 = Reaction123_kon*K_2_0*S_0_m1_0
Reaction124 = Reaction124_koff*S_0_0_0
Reaction125 = Reaction125_kon*K_2_0*S_0_m1_1
Reaction126 = Reaction126_koff*S_0_0_1
Reaction127 = Reaction127_kpon*K_2_1*S_0_m1_m1
Reaction128 = Reaction128_kpoff*S_0_1_m1
Reaction129 = Reaction129_kpon*K_2_1*S_0_m1_0
Reaction130 = Reaction130_kpoff*S_0_1_0
Reaction131 = Reaction131_kpon*K_2_1*S_0_m1_1
Reaction132 = Reaction132_kpoff*S_0_1_1
Reaction133 = Reaction133_kpon*K_2_2*S_0_m1_m1
Reaction134 = Reaction134_kpoff*S_0_2_m1
Reaction135 = Reaction135_kpon*K_2_2*S_0_m1_0
Reaction136 = Reaction136_kpoff*S_0_2_0
Reaction137 = Reaction137_kpon*K_2_2*S_0_m1_1
Reaction138 = Reaction138_kpoff*S_0_2_1
Reaction139 = Reaction139_kon*K_2_0*S_1_m1_m1
Reaction140 = Reaction140_koff*S_1_0_m1
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Reaction141 = Reaction141_kon*K_2_0*S_1_m1_0
Reaction142 = Reaction142_koff*S_1_0_0
Reaction143 = Reaction143_kon*K_2_0*S_1_m1_1
Reaction144 = Reaction144_koff*S_1_0_1
Reaction145 = Reaction145_kpon*K_2_1*S_1_m1_m1
Reaction146 = Reaction146_kpoff*S_1_1_m1
Reaction147 = Reaction147_kpon*K_2_1*S_1_m1_0
Reaction148 = Reaction148_kpoff*S_1_1_0
Reaction149 = Reaction149_kpon*K_2_1*S_1_m1_1
Reaction150 = Reaction150_kpoff*S_1_1_1
Reaction151 = Reaction151_kpon*K_2_2*S_1_m1_m1
Reaction152 = Reaction152_kpoff*S_1_2_m1
Reaction153 = Reaction153_kpon*K_2_2*S_1_m1_0
Reaction154 = Reaction154_kpoff*S_1_2_0
Reaction155 = Reaction155_kpon*K_2_2*S_1_m1_1
Reaction156 = Reaction156_kpoff*S_1_2_1
Reaction157 = Reaction157_kon*K_2_0*S_2_m1_m1
Reaction158 = Reaction158_koff*S_2_0_m1
Reaction159 = Reaction159_kon*K_2_0*S_2_m1_0
Reaction160 = Reaction160_koff*S_2_0_0
Reaction161 = Reaction161_kon*K_2_0*S_2_m1_1
Reaction162 = Reaction162_koff*S_2_0_1
Reaction163 = Reaction163_kpon*K_2_1*S_2_m1_m1
Reaction164 = Reaction164_kpoff*S_2_1_m1
Reaction165 = Reaction165_kpon*K_2_1*S_2_m1_0
Reaction166 = Reaction166_kpoff*S_2_1_0
Reaction167 = Reaction167_kpon*K_2_1*S_2_m1_1
Reaction168 = Reaction168_kpoff*S_2_1_1
Reaction169 = Reaction169_kpon*K_2_2*S_2_m1_m1
Reaction170 = Reaction170_kpoff*S_2_2_m1
Reaction171 = Reaction171_kpon*K_2_2*S_2_m1_0
Reaction172 = Reaction172_kpoff*S_2_2_0
Reaction173 = Reaction173_kpon*K_2_2*S_2_m1_1
Reaction174 = Reaction174_kpoff*S_2_2_1
Reaction175 = Reaction175_kon*K_3_0*S_m1_m1_m1
Reaction176 = Reaction176_koff*S_m1_m1_0
Reaction177 = Reaction177_kpon*K_3_1*S_m1_m1_m1
Reaction178 = Reaction178_kpoff*S_m1_m1_1
Reaction179 = Reaction179_kon*K_3_0*S_m1_0_m1
Reaction180 = Reaction180_koff*S_m1_0_0
Reaction181 = Reaction181_kpon*K_3_1*S_m1_0_m1
Reaction182 = Reaction182_kpoff*S_m1_0_1
Reaction183 = Reaction183_kon*K_3_0*S_m1_1_m1
Reaction184 = Reaction184_koff*S_m1_1_0
Reaction185 = Reaction185_kpon*K_3_1*S_m1_1_m1
Reaction186 = Reaction186_kpoff*S_m1_1_1
Reaction187 = Reaction187_kon*K_3_0*S_m1_2_m1
Reaction188 = Reaction188_koff*S_m1_2_0
Reaction189 = Reaction189_kpon*K_3_1*S_m1_2_m1
Reaction190 = Reaction190_kpoff*S_m1_2_1
Reaction191 = Reaction191_kon*K_3_0*S_0_m1_m1
Reaction192 = Reaction192_koff*S_0_m1_0
Reaction193 = Reaction193_kpon*K_3_1*S_0_m1_m1
Reaction194 = Reaction194_kpoff*S_0_m1_1
Reaction195 = Reaction195_kon*K_3_0*S_0_0_m1

103

Reaction196 = Reaction196_koff*S_0_0_0
Reaction197 = Reaction197_kpon*K_3_1*S_0_0_m1
Reaction198 = Reaction198_kpoff*S_0_0_1
Reaction199 = Reaction199_kon*K_3_0*S_0_1_m1
Reaction200 = Reaction200_koff*S_0_1_0
Reaction201 = Reaction201_kpon*K_3_1*S_0_1_m1
Reaction202 = Reaction202_kpoff*S_0_1_1
Reaction203 = Reaction203_kon*K_3_0*S_0_2_m1
Reaction204 = Reaction204_koff*S_0_2_0
Reaction205 = Reaction205_kpon*K_3_1*S_0_2_m1
Reaction206 = Reaction206_kpoff*S_0_2_1
Reaction207 = Reaction207_kon*K_3_0*S_1_m1_m1
Reaction208 = Reaction208_koff*S_1_m1_0
Reaction209 = Reaction209_kpon*K_3_1*S_1_m1_m1
Reaction210 = Reaction210_kpoff*S_1_m1_1
Reaction211 = Reaction211_kon*K_3_0*S_1_0_m1
Reaction212 = Reaction212_koff*S_1_0_0
Reaction213 = Reaction213_kpon*K_3_1*S_1_0_m1
Reaction214 = Reaction214_kpoff*S_1_0_1
Reaction215 = Reaction215_kon*K_3_0*S_1_1_m1
Reaction216 = Reaction216_koff*S_1_1_0
Reaction217 = Reaction217_kpon*K_3_1*S_1_1_m1
Reaction218 = Reaction218_kpoff*S_1_1_1
Reaction219 = Reaction219_kon*K_3_0*S_1_2_m1
Reaction220 = Reaction220_koff*S_1_2_0
Reaction221 = Reaction221_kpon*K_3_1*S_1_2_m1
Reaction222 = Reaction222_kpoff*S_1_2_1
Reaction223 = Reaction223_kon*K_3_0*S_2_m1_m1
Reaction224 = Reaction224_koff*S_2_m1_0
Reaction225 = Reaction225_kpon*K_3_1*S_2_m1_m1
Reaction226 = Reaction226_kpoff*S_2_m1_1
Reaction227 = Reaction227_kon*K_3_0*S_2_0_m1
Reaction228 = Reaction228_koff*S_2_0_0
Reaction229 = Reaction229_kpon*K_3_1*S_2_0_m1
Reaction230 = Reaction230_kpoff*S_2_0_1
Reaction231 = Reaction231_kon*K_3_0*S_2_1_m1
Reaction232 = Reaction232_koff*S_2_1_0
Reaction233 = Reaction233_kpon*K_3_1*S_2_1_m1
Reaction234 = Reaction234_kpoff*S_2_1_1
Reaction235 = Reaction235_kon*K_3_0*S_2_2_m1
Reaction236 = Reaction236_koff*S_2_2_0
Reaction237 = Reaction237_kpon*K_3_1*S_2_2_m1
Reaction238 = Reaction238_kpoff*S_2_2_1
Reaction239 = Reaction239_k7*S_0_2_m1
Reaction240 = Reaction240_k7*S_0_2_0
Reaction241 = Reaction241_k7*S_0_2_1
Reaction242 = Reaction242_k9a*S_1_2_m1
Reaction243 = Reaction243_k9a*S_1_2_0
Reaction244 = Reaction244_k9a*S_1_2_1
Reaction245 = Reaction245_k3*S_m1_0_1
Reaction246 = Reaction246_k5a*S_m1_1_1
Reaction247 = Reaction247_k3*S_0_0_1
Reaction248 = Reaction248_k5a*S_0_1_1
Reaction249 = Reaction249_k3*S_1_0_1
Reaction250 = Reaction250_k5a*S_1_1_1

104

Reaction251 = Reaction251_k3*S_2_0_1
Reaction252 = Reaction252_k5a*S_2_1_1
Reaction253 = Reaction253_k1a*RAFK*S_m1_m1_0
Reaction254 = Reaction254_d1a*S_RAFK_m1_m1_0
Reaction255 = Reaction255_k1*S_RAFK_m1_m1_0
Reaction256 = Reaction256_k1a*RAFK*S_m1_0_0
Reaction257 = Reaction257_d1a*S_RAFK_m1_0_0
Reaction258 = Reaction258_k1*S_RAFK_m1_0_0
Reaction259 = Reaction259_k1a*RAFK*S_m1_1_0
Reaction260 = Reaction260_d1a*S_RAFK_m1_1_0
Reaction261 = Reaction261_k1*S_RAFK_m1_1_0
Reaction262 = Reaction262_k1a*RAFK*S_m1_2_0
Reaction263 = Reaction263_d1a*S_RAFK_m1_2_0
Reaction264 = Reaction264_k1*S_RAFK_m1_2_0
Reaction265 = Reaction265_k1a*RAFK*S_0_m1_0
Reaction266 = Reaction266_d1a*S_RAFK_0_m1_0
Reaction267 = Reaction267_k1*S_RAFK_0_m1_0
Reaction268 = Reaction268_k1a*RAFK*S_0_0_0
Reaction269 = Reaction269_d1a*S_RAFK_0_0_0
Reaction270 = Reaction270_k1*S_RAFK_0_0_0
Reaction271 = Reaction271_k1a*RAFK*S_0_1_0
Reaction272 = Reaction272_d1a*S_RAFK_0_1_0
Reaction273 = Reaction273_k1*S_RAFK_0_1_0
Reaction274 = Reaction274_k1a*RAFK*S_0_2_0
Reaction275 = Reaction275_d1a*S_RAFK_0_2_0
Reaction276 = Reaction276_k1*S_RAFK_0_2_0
Reaction277 = Reaction277_k1a*RAFK*S_1_m1_0
Reaction278 = Reaction278_d1a*S_RAFK_1_m1_0
Reaction279 = Reaction279_k1*S_RAFK_1_m1_0
Reaction280 = Reaction280_k1a*RAFK*S_1_0_0
Reaction281 = Reaction281_d1a*S_RAFK_1_0_0
Reaction282 = Reaction282_k1*S_RAFK_1_0_0
Reaction283 = Reaction283_k1a*RAFK*S_1_1_0
Reaction284 = Reaction284_d1a*S_RAFK_1_1_0
Reaction285 = Reaction285_k1*S_RAFK_1_1_0
Reaction286 = Reaction286_k1a*RAFK*S_1_2_0
Reaction287 = Reaction287_d1a*S_RAFK_1_2_0
Reaction288 = Reaction288_k1*S_RAFK_1_2_0
Reaction289 = Reaction289_k1a*RAFK*S_2_m1_0
Reaction290 = Reaction290_d1a*S_RAFK_2_m1_0
Reaction291 = Reaction291_k1*S_RAFK_2_m1_0
Reaction292 = Reaction292_k1a*RAFK*S_2_0_0
Reaction293 = Reaction293_d1a*S_RAFK_2_0_0
Reaction294 = Reaction294_k1*S_RAFK_2_0_0
Reaction295 = Reaction295_k1a*RAFK*S_2_1_0
Reaction296 = Reaction296_d1a*S_RAFK_2_1_0
Reaction297 = Reaction297_k1*S_RAFK_2_1_0
Reaction298 = Reaction298_k1a*RAFK*S_2_2_0
Reaction299 = Reaction299_d1a*S_RAFK_2_2_0
Reaction300 = Reaction300_k1*S_RAFK_2_2_0
Cleave_KKP = J301_KKP_k*K_2_1
Cleave_KK = J302_KK_k*K_2_0
Cleave_KKPP = J303_KKPP_k*K_2_2
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; Differential Equations:
Cleaved_MAPKK' = + Cleave_KKP + Cleave_KK + Cleave_KKPP
MAPKP' = - Reaction22 + Reaction23 + Reaction24 - Reaction28 + Reaction29 + Reaction30
MEKP' = - Reaction10 + Reaction11 + Reaction12 - Reaction16 + Reaction17 + Reaction18
RAFK' = - Reaction1 + Reaction2 + Reaction3 - Reaction253 + Reaction254 + Reaction255 Reaction256 + Reaction257 + Reaction258 - Reaction259 + Reaction260 + Reaction261 Reaction262 + Reaction263 + Reaction264 - Reaction265 + Reaction266 + Reaction267 Reaction268 + Reaction269 + Reaction270 - Reaction271 + Reaction272 + Reaction273 Reaction274 + Reaction275 + Reaction276 - Reaction277 + Reaction278 + Reaction279 Reaction280 + Reaction281 + Reaction282 - Reaction283 + Reaction284 + Reaction285 Reaction286 + Reaction287 + Reaction288 - Reaction289 + Reaction290 + Reaction291 Reaction292 + Reaction293 + Reaction294 - Reaction295 + Reaction296 + Reaction297 Reaction298 + Reaction299 + Reaction300
RAFP' = - Reaction4 + Reaction5 + Reaction6
K_1_0' = - Reaction19 + Reaction20 + Reaction24 - Reaction31 + Reaction32 - Reaction33 +
Reaction34 - Reaction35 + Reaction36 - Reaction37 + Reaction38 - Reaction39 + Reaction40 Reaction41 + Reaction42 - Reaction43 + Reaction44 - Reaction45 + Reaction46 - Reaction47 +
Reaction48 - Reaction49 + Reaction50 - Reaction51 + Reaction52 - Reaction53 + Reaction54
K_1_1' = + Reaction21 - Reaction22 + Reaction23 - Reaction25 + Reaction26 + Reaction30 Reaction55 + Reaction56 - Reaction57 + Reaction58 - Reaction59 + Reaction60 - Reaction61 +
Reaction62 - Reaction63 + Reaction64 - Reaction65 + Reaction66 - Reaction67 + Reaction68 Reaction69 + Reaction70 - Reaction71 + Reaction72 - Reaction73 + Reaction74 - Reaction75 +
Reaction76 - Reaction77 + Reaction78
K_1_2' = + Reaction27 - Reaction28 + Reaction29 - Reaction79 + Reaction80 - Reaction81 +
Reaction82 - Reaction83 + Reaction84 - Reaction85 + Reaction86 - Reaction87 + Reaction88 Reaction89 + Reaction90 - Reaction91 + Reaction92 - Reaction93 + Reaction94 - Reaction95 +
Reaction96 - Reaction97 + Reaction98 - Reaction99 + Reaction100 - Reaction101 + Reaction102
K_2_0' = - Reaction7 + Reaction8 + Reaction12 - Reaction103 + Reaction104 - Reaction105 +
Reaction106 - Reaction107 + Reaction108 - Reaction121 + Reaction122 - Reaction123 +
Reaction124 - Reaction125 + Reaction126 - Reaction139 + Reaction140 - Reaction141 +
Reaction142 - Reaction143 + Reaction144 - Reaction157 + Reaction158 - Reaction159 +
Reaction160 - Reaction161 + Reaction162 - Cleave_KK
K_2_1' = + Reaction9 - Reaction10 + Reaction11 - Reaction13 + Reaction14 + Reaction18 Reaction109 + Reaction110 - Reaction111 + Reaction112 - Reaction113 + Reaction114 Reaction127 + Reaction128 - Reaction129 + Reaction130 - Reaction131 + Reaction132 Reaction145 + Reaction146 - Reaction147 + Reaction148 - Reaction149 + Reaction150 Reaction163 + Reaction164 - Reaction165 + Reaction166 - Reaction167 + Reaction168 Cleave_KKP
K_2_2' = + Reaction15 - Reaction16 + Reaction17 - Reaction19 + Reaction20 + Reaction21 Reaction25 + Reaction26 + Reaction27 - Reaction115 + Reaction116 - Reaction117 +
Reaction118 - Reaction119 + Reaction120 - Reaction133 + Reaction134 - Reaction135 +
Reaction136 - Reaction137 + Reaction138 - Reaction151 + Reaction152 - Reaction153 +
Reaction154 - Reaction155 + Reaction156 - Reaction169 + Reaction170 - Reaction171 +
Reaction172 - Reaction173 + Reaction174 - Cleave_KKPP
K_3_0' = - Reaction1 + Reaction2 + Reaction6 - Reaction175 + Reaction176 - Reaction179 +
Reaction180 - Reaction183 + Reaction184 - Reaction187 + Reaction188 - Reaction191 +
Reaction192 - Reaction195 + Reaction196 - Reaction199 + Reaction200 - Reaction203 +
Reaction204 - Reaction207 + Reaction208 - Reaction211 + Reaction212 - Reaction215 +
Reaction216 - Reaction219 + Reaction220 - Reaction223 + Reaction224 - Reaction227 +
Reaction228 - Reaction231 + Reaction232 - Reaction235 + Reaction236
K_3_1' = + Reaction3 - Reaction4 + Reaction5 - Reaction7 + Reaction8 + Reaction9 - Reaction13
+ Reaction14 + Reaction15 - Reaction177 + Reaction178 - Reaction181 + Reaction182 Reaction185 + Reaction186 - Reaction189 + Reaction190 - Reaction193 + Reaction194 Reaction197 + Reaction198 - Reaction201 + Reaction202 - Reaction205 + Reaction206 Reaction209 + Reaction210 - Reaction213 + Reaction214 - Reaction217 + Reaction218 -
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Reaction221 + Reaction222 - Reaction225 + Reaction226 - Reaction229 + Reaction230 Reaction233 + Reaction234 - Reaction237 + Reaction238
K_K_1_0_2_2' = + Reaction19 - Reaction20 - Reaction21
K_K_1_1_2_2' = + Reaction25 - Reaction26 - Reaction27
K_K_2_0_3_1' = + Reaction7 - Reaction8 - Reaction9
K_K_2_1_3_1' = + Reaction13 - Reaction14 - Reaction15
K_MAPKP_1_1' = + Reaction22 - Reaction23 - Reaction24
K_MEKP_2_1' = + Reaction10 - Reaction11 - Reaction12
K_RAFK_3_0' = + Reaction1 - Reaction2 - Reaction3
S_m1_m1_m1' = - Reaction31 + Reaction32 - Reaction55 + Reaction56 - Reaction79 +
Reaction80 - Reaction103 + Reaction104 - Reaction109 + Reaction110 - Reaction115 +
Reaction116 - Reaction175 + Reaction176 - Reaction177 + Reaction178
S_m1_m1_0' = - Reaction33 + Reaction34 - Reaction57 + Reaction58 - Reaction81 + Reaction82
- Reaction105 + Reaction106 - Reaction111 + Reaction112 - Reaction117 + Reaction118 +
Reaction175 - Reaction176 - Reaction253 + Reaction254
S_m1_m1_1' = - Reaction35 + Reaction36 - Reaction59 + Reaction60 - Reaction83 + Reaction84
- Reaction107 + Reaction108 - Reaction113 + Reaction114 - Reaction119 + Reaction120 +
Reaction177 - Reaction178 + Reaction255
S_m1_0_m1' = - Reaction37 + Reaction38 - Reaction61 + Reaction62 - Reaction85 + Reaction86
+ Reaction103 - Reaction104 - Reaction179 + Reaction180 - Reaction181 + Reaction182
S_m1_0_0' = - Reaction39 + Reaction40 - Reaction63 + Reaction64 - Reaction87 + Reaction88 +
Reaction105 - Reaction106 + Reaction179 - Reaction180 - Reaction256 + Reaction257
S_m1_0_1' = - Reaction41 + Reaction42 - Reaction65 + Reaction66 - Reaction89 + Reaction90 +
Reaction107 - Reaction108 + Reaction181 - Reaction182 - Reaction245 + Reaction258
S_m1_1_m1' = - Reaction43 + Reaction44 - Reaction67 + Reaction68 - Reaction91 + Reaction92
+ Reaction109 - Reaction110 - Reaction183 + Reaction184 - Reaction185 + Reaction186
S_m1_1_0' = - Reaction45 + Reaction46 - Reaction69 + Reaction70 - Reaction93 + Reaction94 +
Reaction111 - Reaction112 + Reaction183 - Reaction184 - Reaction259 + Reaction260
S_m1_1_1' = - Reaction47 + Reaction48 - Reaction71 + Reaction72 - Reaction95 + Reaction96 +
Reaction113 - Reaction114 + Reaction185 - Reaction186 + Reaction245 - Reaction246 +
Reaction261
S_m1_2_m1' = - Reaction49 + Reaction50 - Reaction73 + Reaction74 - Reaction97 + Reaction98
+ Reaction115 - Reaction116 - Reaction187 + Reaction188 - Reaction189 + Reaction190
S_m1_2_0' = - Reaction51 + Reaction52 - Reaction75 + Reaction76 - Reaction99 + Reaction100
+ Reaction117 - Reaction118 + Reaction187 - Reaction188 - Reaction262 + Reaction263
S_m1_2_1' = - Reaction53 + Reaction54 - Reaction77 + Reaction78 - Reaction101 + Reaction102
+ Reaction119 - Reaction120 + Reaction189 - Reaction190 + Reaction246 + Reaction264
S_0_m1_m1' = + Reaction31 - Reaction32 - Reaction121 + Reaction122 - Reaction127 +
Reaction128 - Reaction133 + Reaction134 - Reaction191 + Reaction192 - Reaction193 +
Reaction194
S_0_m1_0' = + Reaction33 - Reaction34 - Reaction123 + Reaction124 - Reaction129 +
Reaction130 - Reaction135 + Reaction136 + Reaction191 - Reaction192 - Reaction265 +
Reaction266
S_0_m1_1' = + Reaction35 - Reaction36 - Reaction125 + Reaction126 - Reaction131 +
Reaction132 - Reaction137 + Reaction138 + Reaction193 - Reaction194 + Reaction267
S_0_0_m1' = + Reaction37 - Reaction38 + Reaction121 - Reaction122 - Reaction195 +
Reaction196 - Reaction197 + Reaction198
S_0_0_0' = + Reaction39 - Reaction40 + Reaction123 - Reaction124 + Reaction195 Reaction196 - Reaction268 + Reaction269
S_0_0_1' = + Reaction41 - Reaction42 + Reaction125 - Reaction126 + Reaction197 Reaction198 - Reaction247 + Reaction270
S_0_1_m1' = + Reaction43 - Reaction44 + Reaction127 - Reaction128 - Reaction199 +
Reaction200 - Reaction201 + Reaction202
S_0_1_0' = + Reaction45 - Reaction46 + Reaction129 - Reaction130 + Reaction199 Reaction200 - Reaction271 + Reaction272
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S_0_1_1' = + Reaction47 - Reaction48 + Reaction131 - Reaction132 + Reaction201 Reaction202 + Reaction247 - Reaction248 + Reaction273
S_0_2_m1' = + Reaction49 - Reaction50 + Reaction133 - Reaction134 - Reaction203 +
Reaction204 - Reaction205 + Reaction206 - Reaction239
S_0_2_0' = + Reaction51 - Reaction52 + Reaction135 - Reaction136 + Reaction203 Reaction204 - Reaction240 - Reaction274 + Reaction275
S_0_2_1' = + Reaction53 - Reaction54 + Reaction137 - Reaction138 + Reaction205 Reaction206 - Reaction241 + Reaction248 + Reaction276
S_1_m1_m1' = + Reaction55 - Reaction56 - Reaction139 + Reaction140 - Reaction145 +
Reaction146 - Reaction151 + Reaction152 - Reaction207 + Reaction208 - Reaction209 +
Reaction210
S_1_m1_0' = + Reaction57 - Reaction58 - Reaction141 + Reaction142 - Reaction147 +
Reaction148 - Reaction153 + Reaction154 + Reaction207 - Reaction208 - Reaction277 +
Reaction278
S_1_m1_1' = + Reaction59 - Reaction60 - Reaction143 + Reaction144 - Reaction149 +
Reaction150 - Reaction155 + Reaction156 + Reaction209 - Reaction210 + Reaction279
S_1_0_m1' = + Reaction61 - Reaction62 + Reaction139 - Reaction140 - Reaction211 +
Reaction212 - Reaction213 + Reaction214
S_1_0_0' = + Reaction63 - Reaction64 + Reaction141 - Reaction142 + Reaction211 Reaction212 - Reaction280 + Reaction281
S_1_0_1' = + Reaction65 - Reaction66 + Reaction143 - Reaction144 + Reaction213 Reaction214 - Reaction249 + Reaction282
S_1_1_m1' = + Reaction67 - Reaction68 + Reaction145 - Reaction146 - Reaction215 +
Reaction216 - Reaction217 + Reaction218
S_1_1_0' = + Reaction69 - Reaction70 + Reaction147 - Reaction148 + Reaction215 Reaction216 - Reaction283 + Reaction284
S_1_1_1' = + Reaction71 - Reaction72 + Reaction149 - Reaction150 + Reaction217 Reaction218 + Reaction249 - Reaction250 + Reaction285
S_1_2_m1' = + Reaction73 - Reaction74 + Reaction151 - Reaction152 - Reaction219 +
Reaction220 - Reaction221 + Reaction222 + Reaction239 - Reaction242
S_1_2_0' = + Reaction75 - Reaction76 + Reaction153 - Reaction154 + Reaction219 Reaction220 + Reaction240 - Reaction243 - Reaction286 + Reaction287
S_1_2_1' = + Reaction77 - Reaction78 + Reaction155 - Reaction156 + Reaction221 Reaction222 + Reaction241 - Reaction244 + Reaction250 + Reaction288
S_2_m1_m1' = + Reaction79 - Reaction80 - Reaction157 + Reaction158 - Reaction163 +
Reaction164 - Reaction169 + Reaction170 - Reaction223 + Reaction224 - Reaction225 +
Reaction226
S_2_m1_0' = + Reaction81 - Reaction82 - Reaction159 + Reaction160 - Reaction165 +
Reaction166 - Reaction171 + Reaction172 + Reaction223 - Reaction224 - Reaction289 +
Reaction290
S_2_m1_1' = + Reaction83 - Reaction84 - Reaction161 + Reaction162 - Reaction167 +
Reaction168 - Reaction173 + Reaction174 + Reaction225 - Reaction226 + Reaction291
S_2_0_m1' = + Reaction85 - Reaction86 + Reaction157 - Reaction158 - Reaction227 +
Reaction228 - Reaction229 + Reaction230
S_2_0_0' = + Reaction87 - Reaction88 + Reaction159 - Reaction160 + Reaction227 Reaction228 - Reaction292 + Reaction293
S_2_0_1' = + Reaction89 - Reaction90 + Reaction161 - Reaction162 + Reaction229 Reaction230 - Reaction251 + Reaction294
S_2_1_m1' = + Reaction91 - Reaction92 + Reaction163 - Reaction164 - Reaction231 +
Reaction232 - Reaction233 + Reaction234
S_2_1_0' = + Reaction93 - Reaction94 + Reaction165 - Reaction166 + Reaction231 Reaction232 - Reaction295 + Reaction296
S_2_1_1' = + Reaction95 - Reaction96 + Reaction167 - Reaction168 + Reaction233 Reaction234 + Reaction251 - Reaction252 + Reaction297
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S_2_2_0' = + Reaction99 - Reaction100 + Reaction171 - Reaction172 + Reaction235 Reaction236 + Reaction243 - Reaction298 + Reaction299
S_RAFK_m1_m1_0' = + Reaction253 - Reaction254 - Reaction255
S_RAFK_m1_0_0' = + Reaction256 - Reaction257 - Reaction258
S_RAFK_m1_1_0' = + Reaction259 - Reaction260 - Reaction261
S_RAFK_0_m1_0' = + Reaction265 - Reaction266 - Reaction267
S_RAFK_0_0_0' = + Reaction268 - Reaction269 - Reaction270
S_RAFK_0_1_0' = + Reaction271 - Reaction272 - Reaction273
S_RAFK_0_2_0' = + Reaction274 - Reaction275 - Reaction276
S_RAFK_1_m1_0' = + Reaction277 - Reaction278 - Reaction279
S_RAFK_1_0_0' = + Reaction280 - Reaction281 - Reaction282
S_RAFK_1_1_0' = + Reaction283 - Reaction284 - Reaction285
S_RAFK_1_2_0' = + Reaction286 - Reaction287 - Reaction288
S_RAFK_2_m1_0' = + Reaction289 - Reaction290 - Reaction291
S_RAFK_2_0_0' = + Reaction292 - Reaction293 - Reaction294
S_RAFK_2_1_0' = + Reaction295 - Reaction296 - Reaction297
S_RAFK_m1_2_0' = + Reaction262 - Reaction263 - Reaction264
K_MEKP_2_2' = + Reaction16 - Reaction17 - Reaction18
S_2_2_1' = + Reaction101 - Reaction102 + Reaction173 - Reaction174 + Reaction237 Reaction238 + Reaction244 + Reaction252 + Reaction300
K_MAPKP_1_2' = + Reaction28 - Reaction29 - Reaction30
K_RAFP_3_1' = + Reaction4 - Reaction5 - Reaction6
S_2_2_m1' = + Reaction97 - Reaction98 + Reaction169 - Reaction170 - Reaction235 +
Reaction236 - Reaction237 + Reaction238 + Reaction242
S_RAFK_2_2_0' = + Reaction298 - Reaction299 - Reaction300
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